[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQ-D--WYs2JDI7-qNbG_cUUruUCxsGZbM70Ln0R5gMaE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":84,"rows":91},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",[4],406,false,98,39,104526,48,262,[14,17,19,21,24,26,28,31],{"name":15,"count":16},"HIV Infections",7,{"name":18,"count":16},"Type 1 Diabetes",{"name":20,"count":16},"COPD",{"name":22,"count":23},"Parkinson's Disease",6,{"name":25,"count":23},"HIV",{"name":27,"count":23},"Diabetes Mellitus, Type 1",{"name":29,"count":30},"Coronary Artery Disease",5,{"name":32,"count":30},"Postoperative Pain",[34,39,44,49,54,59,64,69,74,79],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT02780024","Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM","2021-10-20","Metformin",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04169191","Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia","2021-12-31","Sildenafil Citrate",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06021145","Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes","2025-05","Empagliflozin",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05309785","Safety and Efficacy of Canagliflozin in Advanced CKD","2026-03-30","Invokana 300 mg and 100 mg",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06375304","The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study","2026-06-01","B\u002FF\u002FTAF",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07249827","A Randomized Comparison Between 0.67 mcg\u002Fkg, 1 mcg\u002Fkg, and 1.33 mcg\u002Fkg of Perineural Dexmedetomidine for Ultrasound-Guided Infraclavicular Block","2026-06-30","dexmedetomidine (perineural) 0.67 mcg\u002Fkg",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06126419","Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration","2026-07","High-Dose Insulin Therapy",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT07069582","Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women","2026-10-31","Standard dose rifampicin",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04249154","Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer","2026-12-15","Eligard",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06387199","Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide","2027-01","Semaglutide with 4 meal strategies",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,137,173,191,209,233,266,284,302,320,341,361,389,407,433,497,519,561,600,618,636,657,686,704,731,758,776,794,812,837,858,893,911,929,947,973,999,1017,1035,1080,1108,1126,1144,1162,1180,1198,1220,1254,1278,1314,1343,1369,1387,1405,1429,1455,1480,1507,1534,1562,1580,1598,1621,1646,1672,1697,1723,1741,1766,1792,1810,1836,1864,1882,1906,1933,1951,1977,2005,2028,2053,2078,2103,2129,2147,2176,2194,2218,2245,2268,2291,2317,2346,2364,2390,2408,2433,2460,2484,2510,2537,2555,2573,2595,2621,2646,2664,2689,2712,2736,2762,2780,2804,2822,2847,2871,2895,2922,2949,2967,2991,3013,3038,3064,3088,3113,3131,3149,3167,3185,3209,3227,3245,3267,3291,3309,3334,3352,3379,3397,3415,3433,3458,3481,3507,3532,3550,3575,3598,3621,3673,3712,3740,3762,3785,3810,3835,3859,3883,3905,3927,3945,3963,3981,4009,4027,4051,4076,4094,4112,4140,4158,4184,4202,4227,4249,4273,4291,4316,4343,4361,4385,4407,4425,4452,4470,4493,4517,4539,4557,4579,4603,4625,4651,4679,4697,4722,4740,4768,4786,4804],{"intervention":93,"totalTrials":94,"cells":95},"acetaminophen",2,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":117,"NA":135},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT05246644","IV Acetaminophen After Cardiac Surgery - PILOT","UNKNOWN",[88],"2024-09-30","2024-12-15","2023-06-06",900,[115],"Delirium",[93],{"trials":118,"activeCount":134,"soonestReadout":124},[119],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":133},"NCT06613178","Intravenous Acetaminophen After Cardiac Surgery - Definitive Study","RECRUITING",[89],"2027-07-01","2027-12-15","2024-07-02",1100,[129,130,131,132],"Post Operative Delirium","Post Operative Pain","Post-Op Complication","Post-cardiac Surgery",[93],1,{"trials":136,"activeCount":98},[],{"intervention":138,"totalTrials":134,"cells":139},"Clindamycin + primaquine",{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":171},{"trials":141,"activeCount":98},[],{"trials":143,"activeCount":98},[],{"trials":145,"activeCount":98},[],{"trials":147,"activeCount":98},[],{"trials":149,"activeCount":134,"soonestReadout":155},[150],{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":168},"NCT07357103","Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)","NOT_YET_RECRUITING",[89],"2029-03","2029-09","2026-03",416,[160,161,162,163,164,165,166,167],"Pneumocystis","Pneumocystis Infection","Pneumocystis Carinii Infection","Pneumocystis Carinii; Infection, Resulting From HIV Disease","Pneumocystis Jirovecii Pneumonia","Pneumocystis Jirovecii Infection","Pneumocystosis Associated With AIDS","Pneumocystosis; Pneumonia (Etiology)",[138,169,170],"Pentamidine","Atovaquone",{"trials":172,"activeCount":98},[],{"intervention":169,"totalTrials":134,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":189},{"trials":176,"activeCount":98},[],{"trials":178,"activeCount":98},[],{"trials":180,"activeCount":98},[],{"trials":182,"activeCount":98},[],{"trials":184,"activeCount":134,"soonestReadout":155},[185],{"nctId":151,"briefTitle":152,"status":153,"phases":186,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":187,"interventions":188},[89],[160,161,162,163,164,165,166,167],[138,169,170],{"trials":190,"activeCount":98},[],{"intervention":170,"totalTrials":134,"cells":192},{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":201,"NA":207},{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":98},[],{"trials":198,"activeCount":98},[],{"trials":200,"activeCount":98},[],{"trials":202,"activeCount":134,"soonestReadout":155},[203],{"nctId":151,"briefTitle":152,"status":153,"phases":204,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":205,"interventions":206},[89],[160,161,162,163,164,165,166,167],[138,169,170],{"trials":208,"activeCount":98},[],{"intervention":53,"totalTrials":134,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":231},{"trials":212,"activeCount":98},[],{"trials":214,"activeCount":98},[],{"trials":216,"activeCount":98},[],{"trials":218,"activeCount":98},[],{"trials":220,"activeCount":134,"soonestReadout":52},[221],{"nctId":50,"briefTitle":51,"status":222,"phases":223,"primaryCompletion":52,"completion":57,"start":224,"enrollment":225,"conditions":226,"interventions":230},"ACTIVE_NOT_RECRUITING",[89],"2022-11-24",35,[227,228,229],"ESRD","CKD Stage 4","CKD Stage 5",[53],{"trials":232,"activeCount":98},[],{"intervention":234,"totalTrials":134,"cells":235},"Dabigatran",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":244,"NA":264},{"trials":237,"activeCount":98},[],{"trials":239,"activeCount":98},[],{"trials":241,"activeCount":98},[],{"trials":243,"activeCount":98},[],{"trials":245,"activeCount":134,"soonestReadout":250},[246],{"nctId":247,"briefTitle":248,"status":122,"phases":249,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":260},"NCT06650501","Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia",[89],"2030-01","2026-01-15",300,[254,255,256,257,258,259],"Staphylococcus Aureus Endocarditis","Staphylococcus Aureus Septicemia","Staphylococcus Aureus Bacteremia","Staphylococcus Aureus Bloodstream Infection","S. Aureus Bacteremia","S. Aureus Bloodstream Infection",[234,261,262,263],"Apixaban","edoxaban","Rivaroxaban",{"trials":265,"activeCount":98},[],{"intervention":261,"totalTrials":134,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":276,"NA":282},{"trials":269,"activeCount":98},[],{"trials":271,"activeCount":98},[],{"trials":273,"activeCount":98},[],{"trials":275,"activeCount":98},[],{"trials":277,"activeCount":134,"soonestReadout":250},[278],{"nctId":247,"briefTitle":248,"status":122,"phases":279,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":280,"interventions":281},[89],[254,255,256,257,258,259],[234,261,262,263],{"trials":283,"activeCount":98},[],{"intervention":262,"totalTrials":134,"cells":285},{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":294,"NA":300},{"trials":287,"activeCount":98},[],{"trials":289,"activeCount":98},[],{"trials":291,"activeCount":98},[],{"trials":293,"activeCount":98},[],{"trials":295,"activeCount":134,"soonestReadout":250},[296],{"nctId":247,"briefTitle":248,"status":122,"phases":297,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":298,"interventions":299},[89],[254,255,256,257,258,259],[234,261,262,263],{"trials":301,"activeCount":98},[],{"intervention":263,"totalTrials":134,"cells":303},{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":318},{"trials":305,"activeCount":98},[],{"trials":307,"activeCount":98},[],{"trials":309,"activeCount":98},[],{"trials":311,"activeCount":98},[],{"trials":313,"activeCount":134,"soonestReadout":250},[314],{"nctId":247,"briefTitle":248,"status":122,"phases":315,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":316,"interventions":317},[89],[254,255,256,257,258,259],[234,261,262,263],{"trials":319,"activeCount":98},[],{"intervention":58,"totalTrials":134,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":339},{"trials":323,"activeCount":98},[],{"trials":325,"activeCount":98},[],{"trials":327,"activeCount":98},[],{"trials":329,"activeCount":98},[],{"trials":331,"activeCount":134,"soonestReadout":57},[332],{"nctId":55,"briefTitle":56,"status":153,"phases":333,"primaryCompletion":57,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":338},[89],"2027-05-01","2024-05-01",50,[15],[58],{"trials":340,"activeCount":98},[],{"intervention":48,"totalTrials":134,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":359},{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":98},[],{"trials":350,"activeCount":98},[],{"trials":352,"activeCount":134,"soonestReadout":47},[353],{"nctId":45,"briefTitle":46,"status":122,"phases":354,"primaryCompletion":47,"completion":47,"start":355,"enrollment":356,"conditions":357,"interventions":358},[89],"2024-04-02",46,[18],[48],{"trials":360,"activeCount":98},[],{"intervention":362,"totalTrials":134,"cells":363},"Ustekinumab 90 mg SC q8w",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":387},{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":98},[],{"trials":369,"activeCount":98},[],{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":134,"soonestReadout":378},[374],{"nctId":375,"briefTitle":376,"status":122,"phases":377,"primaryCompletion":378,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":385},"NCT07303686","De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis",[89],"2027-04-15","2027-10-15","2025-10-08",115,[383,384],"Crohn Disease (CD)","Ulcerative Colitis (UC)",[362,386],"Ustekinumab 90 mg SC q12w",{"trials":388,"activeCount":98},[],{"intervention":386,"totalTrials":134,"cells":390},{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":405},{"trials":392,"activeCount":98},[],{"trials":394,"activeCount":98},[],{"trials":396,"activeCount":98},[],{"trials":398,"activeCount":98},[],{"trials":400,"activeCount":134,"soonestReadout":378},[401],{"nctId":375,"briefTitle":376,"status":122,"phases":402,"primaryCompletion":378,"completion":379,"start":380,"enrollment":381,"conditions":403,"interventions":404},[89],[383,384],[362,386],{"trials":406,"activeCount":98},[],{"intervention":408,"totalTrials":134,"cells":409},"Systemic corticosteroids",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":431},{"trials":411,"activeCount":98},[],{"trials":413,"activeCount":98},[],{"trials":415,"activeCount":98},[],{"trials":417,"activeCount":98},[],{"trials":419,"activeCount":134,"soonestReadout":424},[420],{"nctId":421,"briefTitle":422,"status":153,"phases":423,"primaryCompletion":424,"completion":425,"start":426,"enrollment":158,"conditions":427,"interventions":430},"NCT07328984","How Long Should we Give Steroids for Patients With Severe PCP",[89],"2029-03-31","2029-06","2026-01-30",[428,160,165,429,163,166,167],"Pneumocystis Pneumonia","Pneumocystis Jiroveci Pneumonia",[408],{"trials":432,"activeCount":98},[],{"intervention":434,"totalTrials":435,"cells":436},"Normal saline",4,{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":455,"PHASE4":457,"NA":484},{"trials":438,"activeCount":98},[],{"trials":440,"activeCount":98},[],{"trials":442,"activeCount":98},[443],{"nctId":444,"briefTitle":445,"status":108,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":453},"NCT02624089","Nebulized Analgesia for Laparoscopic Appendectomy Trial",[86,87],"2017-06","2017-07","2016-01",200,[452],"Appendicitis",[454,434],"Ropivacaine",{"trials":456,"activeCount":98},[],{"trials":458,"activeCount":134,"soonestReadout":475},[459,471],{"nctId":460,"briefTitle":461,"status":462,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":469},"NCT03862404","Intrapleural Bupivacaine for Ipsilateral Shoulder Pain After Thoracotomy","COMPLETED",[89],"2019-02-15","2017-07-01",42,[468],"Post Thoracic Surgery",[470,434],"Bupivacaine-epinephrine",{"nctId":472,"briefTitle":473,"status":122,"phases":474,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":481},"NCT07556952","Dex & Mastectomy Pain",[89],"2028-03-31","2028-06-30","2026-04-13",170,[480],"Post-Mastectomy Chronic Pain Syndrome",[482,483],"Dexamethasone","Normal Saline",{"trials":485,"activeCount":98},[486],{"nctId":487,"briefTitle":488,"status":462,"phases":489,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":496},"NCT03902782","Erector Spinae Plane Block Versus Intercostal for VATS",[90],"2021-06-20","2019-06-26",100,[494,495],"Lung Cancer","Lung Diseases",[470,482,434],{"intervention":482,"totalTrials":94,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":505,"PHASE4":507,"NA":513},{"trials":500,"activeCount":98},[],{"trials":502,"activeCount":98},[],{"trials":504,"activeCount":98},[],{"trials":506,"activeCount":98},[],{"trials":508,"activeCount":134,"soonestReadout":475},[509],{"nctId":472,"briefTitle":473,"status":122,"phases":510,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":511,"interventions":512},[89],[480],[482,483],{"trials":514,"activeCount":98},[515],{"nctId":487,"briefTitle":488,"status":462,"phases":516,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":517,"interventions":518},[90],[494,495],[470,482,434],{"intervention":520,"totalTrials":94,"cells":521},"rifampin double dose",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":542,"PHASE4":557,"NA":559},{"trials":523,"activeCount":98},[],{"trials":525,"activeCount":98},[],{"trials":527,"activeCount":98},[528],{"nctId":529,"briefTitle":530,"status":462,"phases":531,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":538},"NCT03988933","2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.",[87],"2023-01-31","2024-12-31","2019-09-20",1368,[537],"Latent Tuberculosis",[539,540,541],"Rifampin double dose","Rifampin triple dose","Rifampin standard dose",{"trials":543,"activeCount":134,"soonestReadout":548},[544],{"nctId":545,"briefTitle":546,"status":122,"phases":547,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":552,"interventions":554},"NCT06498414","Shorter and Safer Treatment Regimens for Latent TB",[87,88],"2027-04-01","2029-06-01","2025-06-10",1800,[553],"Tuberculosis Infection, Latent",[555,520,556],"rifampin standard arm","levofloxacin and rifapentine",{"trials":558,"activeCount":98},[],{"trials":560,"activeCount":98},[],{"intervention":562,"totalTrials":94,"cells":563},"Vancomycin",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":596,"NA":598},{"trials":565,"activeCount":98},[],{"trials":567,"activeCount":98},[],{"trials":569,"activeCount":98},[],{"trials":571,"activeCount":134,"soonestReadout":576},[572,584],{"nctId":573,"briefTitle":574,"status":122,"phases":575,"primaryCompletion":576,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":582},"NCT07328971","Vancomycin Taper to Prevent Recurrent Clostridioides Difficile",[88],"2030-06-01","2030-11-01","2026-04-24",500,[581],"Clostridia Difficile Colitis",[583,562],"Fidaxomicin",{"nctId":585,"briefTitle":586,"status":462,"phases":587,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":594},"NCT04138706","Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection",[88],"2024-10-04","2024-11-22","2020-11-19",263,[593],"Clostridium Difficile Infection",[562,595],"Placebos",{"trials":597,"activeCount":98},[],{"trials":599,"activeCount":98},[],{"intervention":555,"totalTrials":134,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":614,"NA":616},{"trials":603,"activeCount":98},[],{"trials":605,"activeCount":98},[],{"trials":607,"activeCount":98},[],{"trials":609,"activeCount":134,"soonestReadout":548},[610],{"nctId":545,"briefTitle":546,"status":122,"phases":611,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":612,"interventions":613},[87,88],[553],[555,520,556],{"trials":615,"activeCount":98},[],{"trials":617,"activeCount":98},[],{"intervention":556,"totalTrials":134,"cells":619},{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":632,"NA":634},{"trials":621,"activeCount":98},[],{"trials":623,"activeCount":98},[],{"trials":625,"activeCount":98},[],{"trials":627,"activeCount":134,"soonestReadout":548},[628],{"nctId":545,"briefTitle":546,"status":122,"phases":629,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":630,"interventions":631},[87,88],[553],[555,520,556],{"trials":633,"activeCount":98},[],{"trials":635,"activeCount":98},[],{"intervention":83,"totalTrials":134,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":653,"NA":655},{"trials":639,"activeCount":98},[],{"trials":641,"activeCount":98},[],{"trials":643,"activeCount":98},[],{"trials":645,"activeCount":134,"soonestReadout":82},[646],{"nctId":80,"briefTitle":81,"status":122,"phases":647,"primaryCompletion":82,"completion":82,"start":648,"enrollment":649,"conditions":650,"interventions":652},[87,88],"2024-12-01",26,[18,651],"Diabetes Mellitus",[83],{"trials":654,"activeCount":98},[],{"trials":656,"activeCount":98},[],{"intervention":658,"totalTrials":134,"cells":659},"Tirzepatide",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":682,"NA":684},{"trials":661,"activeCount":98},[],{"trials":663,"activeCount":98},[],{"trials":665,"activeCount":98},[],{"trials":667,"activeCount":134,"soonestReadout":672},[668],{"nctId":669,"briefTitle":670,"status":122,"phases":671,"primaryCompletion":672,"completion":673,"start":674,"enrollment":675,"conditions":676,"interventions":681},"NCT07284511","A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar",[87,88],"2028-01","2029-01","2026-05-19",105,[18,677,678,679,680],"Type 1 Diabetes Mellitus","T1D","T1DM","T1DM - Type 1 Diabetes Mellitus",[658],{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":98},[],{"intervention":583,"totalTrials":134,"cells":687},{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":700,"NA":702},{"trials":689,"activeCount":98},[],{"trials":691,"activeCount":98},[],{"trials":693,"activeCount":98},[],{"trials":695,"activeCount":134,"soonestReadout":576},[696],{"nctId":573,"briefTitle":574,"status":122,"phases":697,"primaryCompletion":576,"completion":577,"start":578,"enrollment":579,"conditions":698,"interventions":699},[88],[581],[583,562],{"trials":701,"activeCount":98},[],{"trials":703,"activeCount":98},[],{"intervention":705,"totalTrials":134,"cells":706},"Oral Vancomycin Prophylaxis",{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":727,"NA":729},{"trials":708,"activeCount":98},[],{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":134,"soonestReadout":719},[715],{"nctId":716,"briefTitle":717,"status":122,"phases":718,"primaryCompletion":719,"completion":720,"start":721,"enrollment":252,"conditions":722,"interventions":726},"NCT06979609","Secondary Prevention of Clostridioides Difficile Using Vancomycin",[87,88],"2028-10-01","2029-10-01","2025-10-01",[723,724,725],"Clostridioides Difficile Infection","Clostridioides Difficile Infection Recurrence","Clostridoides Difficile Associated Disease",[705],{"trials":728,"activeCount":98},[],{"trials":730,"activeCount":98},[],{"intervention":732,"totalTrials":134,"cells":733},"Intervention Period 1: Semaglutide + Empagliflozin",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":754,"NA":756},{"trials":735,"activeCount":98},[],{"trials":737,"activeCount":98},[],{"trials":739,"activeCount":98},[],{"trials":741,"activeCount":134,"soonestReadout":82},[742],{"nctId":743,"briefTitle":744,"status":122,"phases":745,"primaryCompletion":82,"completion":82,"start":746,"enrollment":747,"conditions":748,"interventions":750},"NCT06894784","A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes",[88],"2025-04",36,[749],"Diabetes Type 1",[732,751,752,753],"Intervention Period 2: Semaglutide + Empagliflozin Placebo","Intervention Period 3: Semaglutide Placebo + Empagliflozin","Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo",{"trials":755,"activeCount":98},[],{"trials":757,"activeCount":98},[],{"intervention":751,"totalTrials":134,"cells":759},{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":772,"NA":774},{"trials":761,"activeCount":98},[],{"trials":763,"activeCount":98},[],{"trials":765,"activeCount":98},[],{"trials":767,"activeCount":134,"soonestReadout":82},[768],{"nctId":743,"briefTitle":744,"status":122,"phases":769,"primaryCompletion":82,"completion":82,"start":746,"enrollment":747,"conditions":770,"interventions":771},[88],[749],[732,751,752,753],{"trials":773,"activeCount":98},[],{"trials":775,"activeCount":98},[],{"intervention":752,"totalTrials":134,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":790,"NA":792},{"trials":779,"activeCount":98},[],{"trials":781,"activeCount":98},[],{"trials":783,"activeCount":98},[],{"trials":785,"activeCount":134,"soonestReadout":82},[786],{"nctId":743,"briefTitle":744,"status":122,"phases":787,"primaryCompletion":82,"completion":82,"start":746,"enrollment":747,"conditions":788,"interventions":789},[88],[749],[732,751,752,753],{"trials":791,"activeCount":98},[],{"trials":793,"activeCount":98},[],{"intervention":753,"totalTrials":134,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":808,"NA":810},{"trials":797,"activeCount":98},[],{"trials":799,"activeCount":98},[],{"trials":801,"activeCount":98},[],{"trials":803,"activeCount":134,"soonestReadout":82},[804],{"nctId":743,"briefTitle":744,"status":122,"phases":805,"primaryCompletion":82,"completion":82,"start":746,"enrollment":747,"conditions":806,"interventions":807},[88],[749],[732,751,752,753],{"trials":809,"activeCount":98},[],{"trials":811,"activeCount":98},[],{"intervention":813,"totalTrials":134,"cells":814},"Canagliflozin 300Mg Tab",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":816,"activeCount":98},[],{"trials":818,"activeCount":98},[],{"trials":820,"activeCount":134,"soonestReadout":825},[821],{"nctId":822,"briefTitle":823,"status":122,"phases":824,"primaryCompletion":825,"completion":826,"start":335,"enrollment":827,"conditions":828,"interventions":830},"NCT06182839","Canagliflozin in Advanced Renal Disease With MRI Endpoints",[87],"2028-03-30","2029-03-30",92,[829],"ESRD, CKD Stage 4, CKD Stage 5",[813],{"trials":832,"activeCount":98},[],{"trials":834,"activeCount":98},[],{"trials":836,"activeCount":98},[],{"intervention":78,"totalTrials":134,"cells":838},{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":840,"activeCount":98},[],{"trials":842,"activeCount":98},[],{"trials":844,"activeCount":134,"soonestReadout":77},[845],{"nctId":75,"briefTitle":76,"status":122,"phases":846,"primaryCompletion":77,"completion":125,"start":847,"enrollment":848,"conditions":849,"interventions":851},[87],"2019-09-03",77,[850],"Prostate Cancer",[78],{"trials":853,"activeCount":98},[],{"trials":855,"activeCount":98},[],{"trials":857,"activeCount":98},[],{"intervention":859,"totalTrials":134,"cells":860},"Inactivated influenza vaccine (IIV) at baseline",{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":887,"PHASE4":889,"NA":891},{"trials":862,"activeCount":98},[],{"trials":864,"activeCount":98},[],{"trials":866,"activeCount":134,"soonestReadout":871},[867],{"nctId":868,"briefTitle":869,"status":122,"phases":870,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":874,"interventions":883},"NCT06599658","COVID-19 Booster and IIV Schedule in Immunocompromised Hosts",[87],"2027-03-31","2024-11-20",660,[875,876,877,878,879,880,881,882],"COVID 19","Influenza","Rheumatoid Arthritis (RA)","Systemic Lupus Erthematosus","Inflammatory Bowel Disease","Solid Organ Transplant Recipients","Immunocompromised Host","People Living With HIV",[859,884,885,886],"COVID-19 Vaccines at a 3-month interval","Inactivated influenza vaccine at Month 1","COVID-19 Vaccines at a 6-month interval",{"trials":888,"activeCount":98},[],{"trials":890,"activeCount":98},[],{"trials":892,"activeCount":98},[],{"intervention":884,"totalTrials":134,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":896,"activeCount":98},[],{"trials":898,"activeCount":98},[],{"trials":900,"activeCount":134,"soonestReadout":871},[901],{"nctId":868,"briefTitle":869,"status":122,"phases":902,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":903,"interventions":904},[87],[875,876,877,878,879,880,881,882],[859,884,885,886],{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":98},[],{"trials":910,"activeCount":98},[],{"intervention":885,"totalTrials":134,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":914,"activeCount":98},[],{"trials":916,"activeCount":98},[],{"trials":918,"activeCount":134,"soonestReadout":871},[919],{"nctId":868,"briefTitle":869,"status":122,"phases":920,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":921,"interventions":922},[87],[875,876,877,878,879,880,881,882],[859,884,885,886],{"trials":924,"activeCount":98},[],{"trials":926,"activeCount":98},[],{"trials":928,"activeCount":98},[],{"intervention":886,"totalTrials":134,"cells":930},{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":134,"soonestReadout":871},[937],{"nctId":868,"briefTitle":869,"status":122,"phases":938,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":939,"interventions":940},[87],[875,876,877,878,879,880,881,882],[859,884,885,886],{"trials":942,"activeCount":98},[],{"trials":944,"activeCount":98},[],{"trials":946,"activeCount":98},[],{"intervention":948,"totalTrials":134,"cells":949},"Canagliflozin 300 MG",{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":951,"activeCount":98},[],{"trials":953,"activeCount":98},[],{"trials":955,"activeCount":134,"soonestReadout":960},[956],{"nctId":957,"briefTitle":958,"status":122,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":966},"NCT06913647","Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis",[87],"2028-02-28","2028-12-31","2026-02-01",30,[227,965],"CKD (Chronic Kidney Disease) Stage 5D",[948],{"trials":968,"activeCount":98},[],{"trials":970,"activeCount":98},[],{"trials":972,"activeCount":98},[],{"intervention":63,"totalTrials":134,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":976,"activeCount":98},[],{"trials":978,"activeCount":98},[],{"trials":980,"activeCount":134,"soonestReadout":62},[981],{"nctId":60,"briefTitle":61,"status":122,"phases":982,"primaryCompletion":62,"completion":62,"start":983,"enrollment":984,"conditions":985,"interventions":990},[87],"2025-12-28",69,[986,987,988,989],"Analgesia","Pain, Acute","Upper Extremity Surgery","Nerve Block",[63,991,992],"dexmedetomidine (perineural) 1 mcg\u002Fkg","dexmedetomidine (perineural) 1.33 mcg\u002Fkg",{"trials":994,"activeCount":98},[],{"trials":996,"activeCount":98},[],{"trials":998,"activeCount":98},[],{"intervention":991,"totalTrials":134,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1011,"PHASE4":1013,"NA":1015},{"trials":1002,"activeCount":98},[],{"trials":1004,"activeCount":98},[],{"trials":1006,"activeCount":134,"soonestReadout":62},[1007],{"nctId":60,"briefTitle":61,"status":122,"phases":1008,"primaryCompletion":62,"completion":62,"start":983,"enrollment":984,"conditions":1009,"interventions":1010},[87],[986,987,988,989],[63,991,992],{"trials":1012,"activeCount":98},[],{"trials":1014,"activeCount":98},[],{"trials":1016,"activeCount":98},[],{"intervention":992,"totalTrials":134,"cells":1018},{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1029,"PHASE4":1031,"NA":1033},{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[],{"trials":1024,"activeCount":134,"soonestReadout":62},[1025],{"nctId":60,"briefTitle":61,"status":122,"phases":1026,"primaryCompletion":62,"completion":62,"start":983,"enrollment":984,"conditions":1027,"interventions":1028},[87],[986,987,988,989],[63,991,992],{"trials":1030,"activeCount":98},[],{"trials":1032,"activeCount":98},[],{"trials":1034,"activeCount":98},[],{"intervention":38,"totalTrials":1036,"cells":1037},3,{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1053,"PHASE3":1062,"PHASE4":1064,"NA":1066},{"trials":1039,"activeCount":98},[],{"trials":1041,"activeCount":98},[1042],{"nctId":1043,"briefTitle":1044,"status":462,"phases":1045,"primaryCompletion":1046,"completion":1047,"start":1048,"enrollment":1049,"conditions":1050,"interventions":1052},"NCT02659306","Metformin Immunotherapy in HIV Infection",[86],"2018-08-14","2020-02","2016-09",22,[1051],"HIV Infection",[38],{"trials":1054,"activeCount":134,"soonestReadout":37},[1055],{"nctId":35,"briefTitle":36,"status":222,"phases":1056,"primaryCompletion":37,"completion":1057,"start":1058,"enrollment":336,"conditions":1059,"interventions":1061},[87],"2027-02-28","2015-03",[1060],"Glioblastoma Multiforme",[38],{"trials":1063,"activeCount":98},[],{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[1068],{"nctId":1069,"briefTitle":1070,"status":1071,"phases":1072,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":16,"conditions":1075,"interventions":1079},"NCT02393573","Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism","TERMINATED",[90],"2018-03","2015-11",[1076,1077,1078],"Pre-Diabetes","Major Lung or Abdominal Surgery","Insulin Resistance",[38],{"intervention":73,"totalTrials":134,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1100,"PHASE3":1102,"PHASE4":1104,"NA":1106},{"trials":1083,"activeCount":98},[],{"trials":1085,"activeCount":134,"soonestReadout":72},[1086],{"nctId":70,"briefTitle":71,"status":153,"phases":1087,"primaryCompletion":72,"completion":72,"start":1088,"enrollment":1089,"conditions":1090,"interventions":1094},[86],"2026-04-01",60,[1091,1092,1093],"Tuberculosis Infection","Healthy Volunteer","Breastfeeding",[73,1095,1096,1097,1098,1099],"High dose rifampicin","Standard dose isoniazid","Standard dose levofloxacin","Standard dose rifapentine","Standard dose bedaquiline",{"trials":1101,"activeCount":98},[],{"trials":1103,"activeCount":98},[],{"trials":1105,"activeCount":98},[],{"trials":1107,"activeCount":98},[],{"intervention":1095,"totalTrials":134,"cells":1109},{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1111,"activeCount":98},[],{"trials":1113,"activeCount":134,"soonestReadout":72},[1114],{"nctId":70,"briefTitle":71,"status":153,"phases":1115,"primaryCompletion":72,"completion":72,"start":1088,"enrollment":1089,"conditions":1116,"interventions":1117},[86],[1091,1092,1093],[73,1095,1096,1097,1098,1099],{"trials":1119,"activeCount":98},[],{"trials":1121,"activeCount":98},[],{"trials":1123,"activeCount":98},[],{"trials":1125,"activeCount":98},[],{"intervention":1096,"totalTrials":134,"cells":1127},{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1142},{"trials":1129,"activeCount":98},[],{"trials":1131,"activeCount":134,"soonestReadout":72},[1132],{"nctId":70,"briefTitle":71,"status":153,"phases":1133,"primaryCompletion":72,"completion":72,"start":1088,"enrollment":1089,"conditions":1134,"interventions":1135},[86],[1091,1092,1093],[73,1095,1096,1097,1098,1099],{"trials":1137,"activeCount":98},[],{"trials":1139,"activeCount":98},[],{"trials":1141,"activeCount":98},[],{"trials":1143,"activeCount":98},[],{"intervention":1097,"totalTrials":134,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1154,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1147,"activeCount":98},[],{"trials":1149,"activeCount":134,"soonestReadout":72},[1150],{"nctId":70,"briefTitle":71,"status":153,"phases":1151,"primaryCompletion":72,"completion":72,"start":1088,"enrollment":1089,"conditions":1152,"interventions":1153},[86],[1091,1092,1093],[73,1095,1096,1097,1098,1099],{"trials":1155,"activeCount":98},[],{"trials":1157,"activeCount":98},[],{"trials":1159,"activeCount":98},[],{"trials":1161,"activeCount":98},[],{"intervention":1098,"totalTrials":134,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1172,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1165,"activeCount":98},[],{"trials":1167,"activeCount":134,"soonestReadout":72},[1168],{"nctId":70,"briefTitle":71,"status":153,"phases":1169,"primaryCompletion":72,"completion":72,"start":1088,"enrollment":1089,"conditions":1170,"interventions":1171},[86],[1091,1092,1093],[73,1095,1096,1097,1098,1099],{"trials":1173,"activeCount":98},[],{"trials":1175,"activeCount":98},[],{"trials":1177,"activeCount":98},[],{"trials":1179,"activeCount":98},[],{"intervention":1099,"totalTrials":134,"cells":1181},{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1190,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1183,"activeCount":98},[],{"trials":1185,"activeCount":134,"soonestReadout":72},[1186],{"nctId":70,"briefTitle":71,"status":153,"phases":1187,"primaryCompletion":72,"completion":72,"start":1088,"enrollment":1089,"conditions":1188,"interventions":1189},[86],[1091,1092,1093],[73,1095,1096,1097,1098,1099],{"trials":1191,"activeCount":98},[],{"trials":1193,"activeCount":98},[],{"trials":1195,"activeCount":98},[],{"trials":1197,"activeCount":98},[],{"intervention":43,"totalTrials":134,"cells":1199},{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1212,"PHASE3":1214,"PHASE4":1216,"NA":1218},{"trials":1201,"activeCount":98},[],{"trials":1203,"activeCount":134,"soonestReadout":42},[1204],{"nctId":40,"briefTitle":41,"status":222,"phases":1205,"primaryCompletion":42,"completion":1206,"start":1207,"enrollment":1208,"conditions":1209,"interventions":1211},[86],"2024-12","2019-09-19",20,[1210],"Birth Asphyxia",[43],{"trials":1213,"activeCount":98},[],{"trials":1215,"activeCount":98},[],{"trials":1217,"activeCount":98},[],{"trials":1219,"activeCount":98},[],{"intervention":1221,"totalTrials":94,"cells":1222},"Fosigotifator",{"EARLY_PHASE1":1223,"PHASE1":1236,"PHASE2":1238,"PHASE3":1240,"PHASE4":1242,"NA":1244},{"trials":1224,"activeCount":134,"soonestReadout":1229},[1225],{"nctId":1226,"briefTitle":1227,"status":222,"phases":1228,"primaryCompletion":1229,"completion":1230,"start":1231,"enrollment":134,"conditions":1232,"interventions":1235},"NCT07272525","Research Study for Single-Patient Treatment of Cree Leukoencephalopathy\u002FVanishing White Matter Disease",[85],"2027-11-30","2027-12-31","2024-11-14",[1233,1234],"Cree Leukoencephalopathy","Vanishing White Matter",[1221],{"trials":1237,"activeCount":98},[],{"trials":1239,"activeCount":98},[],{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":134,"soonestReadout":1250},[1246],{"nctId":1247,"briefTitle":1248,"status":222,"phases":1249,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":134,"conditions":1252,"interventions":1253},"NCT07300397","Single Patient Investigational Treatment for Cree Leukoencephalopathy",[90],"2029-01-03","2025-12-03",[1233],[1221],{"intervention":68,"totalTrials":134,"cells":1255},{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1266},{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[],{"trials":1261,"activeCount":98},[],{"trials":1263,"activeCount":98},[],{"trials":1265,"activeCount":98},[],{"trials":1267,"activeCount":134,"soonestReadout":67},[1268],{"nctId":65,"briefTitle":66,"status":122,"phases":1269,"primaryCompletion":67,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1277},[90],"2026-12","2023-11-08",70,[1274,1275,1276],"Liver Dysfunction","Liver Metastasis Colon Cancer","Liver Regeneration",[68],{"intervention":1279,"totalTrials":94,"cells":1280},"Saline",{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1287,"PHASE4":1289,"NA":1312},{"trials":1282,"activeCount":98},[],{"trials":1284,"activeCount":98},[],{"trials":1286,"activeCount":98},[],{"trials":1288,"activeCount":98},[],{"trials":1290,"activeCount":98},[1291,1302],{"nctId":1292,"briefTitle":1293,"status":462,"phases":1294,"primaryCompletion":1058,"completion":1074,"start":1295,"enrollment":1296,"conditions":1297,"interventions":1300},"NCT02618772","Intranasal Midazolam for Treatment of Anxiety in Children Undergoing Suturing in the Pediatric Emergency Department",[89],"2010-01",79,[1298,1299],"Anxiety","Lacerations",[1301,1279],"Midazolam",{"nctId":1303,"briefTitle":1304,"status":108,"phases":1305,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1208,"conditions":1308,"interventions":1310},"NCT01328132","Effect of Hyperoncotic Albumin on Vascular Hemodynamics and Oxygen Delivery Following Orthotopic Liver Transplant",[89],"2011-10","2011-03",[1309],"Other Complications of Liver Transplant",[1279,1311],"25% albumin",{"trials":1313,"activeCount":98},[],{"intervention":454,"totalTrials":94,"cells":1315},{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1326,"PHASE4":1328,"NA":1341},{"trials":1317,"activeCount":98},[],{"trials":1319,"activeCount":98},[],{"trials":1321,"activeCount":98},[1322],{"nctId":444,"briefTitle":445,"status":108,"phases":1323,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":1324,"interventions":1325},[86,87],[452],[454,434],{"trials":1327,"activeCount":98},[],{"trials":1329,"activeCount":98},[1330],{"nctId":1331,"briefTitle":1332,"status":108,"phases":1333,"primaryCompletion":1334,"completion":1335,"start":1336,"enrollment":356,"conditions":1337,"interventions":1340},"NCT05755334","Ropivacaine Pharmacokinetics After Erector Spinae Block",[89],"2024-03-01","2024-11-01","2023-06-01",[1338,1339],"Pain","Spinal Fusion",[454],{"trials":1342,"activeCount":98},[],{"intervention":1344,"totalTrials":134,"cells":1345},"PEG\u002Felectrolytes 2L\u002F2L split dose",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1367},{"trials":1347,"activeCount":98},[],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":98},[1356],{"nctId":1357,"briefTitle":1358,"status":1071,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1362,"conditions":1363,"interventions":1365},"NCT02119000","Comparison of Two Types of Bowel Preparation for Inpatient Colonoscopy",[89],"2020-01","2015-08",82,[1364],"Hospitalized Patients",[1344,1366],"Bisacodyl 15 mg and PEG\u002Felectrolytes 1L\u002F1L split dose",{"trials":1368,"activeCount":98},[],{"intervention":1366,"totalTrials":134,"cells":1370},{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1379,"NA":1385},{"trials":1372,"activeCount":98},[],{"trials":1374,"activeCount":98},[],{"trials":1376,"activeCount":98},[],{"trials":1378,"activeCount":98},[],{"trials":1380,"activeCount":98},[1381],{"nctId":1357,"briefTitle":1358,"status":1071,"phases":1382,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1362,"conditions":1383,"interventions":1384},[89],[1364],[1344,1366],{"trials":1386,"activeCount":98},[],{"intervention":1301,"totalTrials":134,"cells":1388},{"EARLY_PHASE1":1389,"PHASE1":1391,"PHASE2":1393,"PHASE3":1395,"PHASE4":1397,"NA":1403},{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[],{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":98},[1399],{"nctId":1292,"briefTitle":1293,"status":462,"phases":1400,"primaryCompletion":1058,"completion":1074,"start":1295,"enrollment":1296,"conditions":1401,"interventions":1402},[89],[1298,1299],[1301,1279],{"trials":1404,"activeCount":98},[],{"intervention":1406,"totalTrials":134,"cells":1407},"Switch to Triumeq",{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1412,"PHASE3":1414,"PHASE4":1416,"NA":1427},{"trials":1409,"activeCount":98},[],{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[],{"trials":1415,"activeCount":98},[],{"trials":1417,"activeCount":98},[1418],{"nctId":1419,"briefTitle":1420,"status":462,"phases":1421,"primaryCompletion":1422,"completion":1423,"start":1074,"enrollment":1424,"conditions":1425,"interventions":1426},"NCT02354053","Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations",[89],"2018-07-03","2019-07-02",27,[15],[1406],{"trials":1428,"activeCount":98},[],{"intervention":1430,"totalTrials":134,"cells":1431},"Methylphenidate or amphetamine product",{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1438,"PHASE4":1440,"NA":1453},{"trials":1433,"activeCount":98},[],{"trials":1435,"activeCount":98},[],{"trials":1437,"activeCount":98},[],{"trials":1439,"activeCount":98},[],{"trials":1441,"activeCount":98},[1442],{"nctId":1443,"briefTitle":1444,"status":108,"phases":1445,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":1450,"interventions":1452},"NCT02566824","Cognitive Behavioral Therapy for Adolescents With Attention-Deficit \u002F Hyperactivity Disorder",[89],"2020-08","2020-10","2010-10",216,[1451],"Attention Deficit Hyperactivity Disorder",[1430],{"trials":1454,"activeCount":98},[],{"intervention":1456,"totalTrials":134,"cells":1457},"Bupropion",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1464,"PHASE4":1466,"NA":1478},{"trials":1459,"activeCount":98},[],{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[],{"trials":1467,"activeCount":98},[1468],{"nctId":1469,"briefTitle":1470,"status":108,"phases":1471,"primaryCompletion":1472,"completion":1472,"start":1473,"enrollment":1474,"conditions":1475,"interventions":1477},"NCT01583023","Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression",[89],"2015-04","2014-04",45,[1476],"Bipolar Disorder",[1456],{"trials":1479,"activeCount":98},[],{"intervention":1481,"totalTrials":134,"cells":1482},"Empagliflozin 25 MG",{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1491,"NA":1505},{"trials":1484,"activeCount":98},[],{"trials":1486,"activeCount":98},[],{"trials":1488,"activeCount":98},[],{"trials":1490,"activeCount":98},[],{"trials":1492,"activeCount":98},[1493],{"nctId":1494,"briefTitle":1495,"status":462,"phases":1496,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1501,"interventions":1504},"NCT05305495","Empagliflozin in Acute Heart Failure",[89],"2026-02-15","2026-03-10","2022-12-22",25,[1502,1503],"Acute Heart Failure","Chronic Kidney Diseases",[1481],{"trials":1506,"activeCount":98},[],{"intervention":1508,"totalTrials":134,"cells":1509},"Daptomycin",{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1516,"PHASE4":1518,"NA":1532},{"trials":1511,"activeCount":98},[],{"trials":1513,"activeCount":98},[],{"trials":1515,"activeCount":98},[],{"trials":1517,"activeCount":98},[],{"trials":1519,"activeCount":98},[1520],{"nctId":1521,"briefTitle":1522,"status":462,"phases":1523,"primaryCompletion":1524,"completion":1525,"start":1526,"enrollment":1527,"conditions":1528,"interventions":1531},"NCT02972983","Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia",[89],"2019-07","2019-09","2016-12-01",102,[1529,1530],"Methicillin Susceptible Staphylococcus Aureus Septicemia","Bacteremia",[1508],{"trials":1533,"activeCount":98},[],{"intervention":1535,"totalTrials":134,"cells":1536},"Ticagrelor 90mg",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1545,"NA":1560},{"trials":1538,"activeCount":98},[],{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":98},[],{"trials":1544,"activeCount":98},[],{"trials":1546,"activeCount":98},[1547],{"nctId":1548,"briefTitle":1549,"status":462,"phases":1550,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":1555,"interventions":1557},"NCT04057300","Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes",[89],"2022-04-01","2023-04-01","2018-10-01",1038,[1556],"Acute Coronary Syndrome",[1535,1558,1559],"Clopidogrel 75mg","acetylsalicylic acid (ASA) 81mg",{"trials":1561,"activeCount":98},[],{"intervention":1558,"totalTrials":134,"cells":1563},{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1568,"PHASE3":1570,"PHASE4":1572,"NA":1578},{"trials":1565,"activeCount":98},[],{"trials":1567,"activeCount":98},[],{"trials":1569,"activeCount":98},[],{"trials":1571,"activeCount":98},[],{"trials":1573,"activeCount":98},[1574],{"nctId":1548,"briefTitle":1549,"status":462,"phases":1575,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":1576,"interventions":1577},[89],[1556],[1535,1558,1559],{"trials":1579,"activeCount":98},[],{"intervention":1559,"totalTrials":134,"cells":1581},{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1588,"PHASE4":1590,"NA":1596},{"trials":1583,"activeCount":98},[],{"trials":1585,"activeCount":98},[],{"trials":1587,"activeCount":98},[],{"trials":1589,"activeCount":98},[],{"trials":1591,"activeCount":98},[1592],{"nctId":1548,"briefTitle":1549,"status":462,"phases":1593,"primaryCompletion":1551,"completion":1552,"start":1553,"enrollment":1554,"conditions":1594,"interventions":1595},[89],[1556],[1535,1558,1559],{"trials":1597,"activeCount":98},[],{"intervention":1599,"totalTrials":134,"cells":1600},"Integrase Inhibitor",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1609,"NA":1619},{"trials":1602,"activeCount":98},[],{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":98},[],{"trials":1608,"activeCount":98},[],{"trials":1610,"activeCount":98},[1611],{"nctId":1612,"briefTitle":1613,"status":462,"phases":1614,"primaryCompletion":1615,"completion":1615,"start":1616,"enrollment":23,"conditions":1617,"interventions":1618},"NCT02691065","Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection",[89],"2021-03-31","2017-01-20",[25],[1599],{"trials":1620,"activeCount":98},[],{"intervention":1622,"totalTrials":134,"cells":1623},"inhaled fluticasone 750 mcg\u002Fday twice daily until 2 days without symptoms",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1630,"PHASE4":1632,"NA":1644},{"trials":1625,"activeCount":98},[],{"trials":1627,"activeCount":98},[],{"trials":1629,"activeCount":98},[],{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[1634],{"nctId":1635,"briefTitle":1636,"status":462,"phases":1637,"primaryCompletion":1638,"completion":1638,"start":1639,"enrollment":1640,"conditions":1641,"interventions":1643},"NCT00238927","Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With Asthma",[89],"2005-09","1999-11",150,[1642],"Asthma",[1622],{"trials":1645,"activeCount":98},[],{"intervention":1647,"totalTrials":134,"cells":1648},"Albendazole",{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1655,"PHASE4":1657,"NA":1670},{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[],{"trials":1654,"activeCount":98},[],{"trials":1656,"activeCount":98},[],{"trials":1658,"activeCount":98},[1659],{"nctId":1660,"briefTitle":1661,"status":462,"phases":1662,"primaryCompletion":1663,"completion":1664,"start":1665,"enrollment":1666,"conditions":1667,"interventions":1669},"NCT01748929","Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth",[89],"2015-02-13","2016-09-16","2014-02-24",1010,[1668],"Intestinal Diseases, Parasitic",[1647],{"trials":1671,"activeCount":98},[],{"intervention":1673,"totalTrials":134,"cells":1674},"propofol",{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1681,"PHASE4":1683,"NA":1695},{"trials":1676,"activeCount":98},[],{"trials":1678,"activeCount":98},[],{"trials":1680,"activeCount":98},[],{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[1685],{"nctId":1686,"briefTitle":1687,"status":462,"phases":1688,"primaryCompletion":1689,"start":1690,"enrollment":1691,"conditions":1692,"interventions":1694},"NCT01019746","Controlled Propofol Administration",[89],"2008-05","2007-08",40,[1693],"HYPNOSIS",[1673],{"trials":1696,"activeCount":98},[],{"intervention":1698,"totalTrials":134,"cells":1699},"Ranibizumab",{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1704,"PHASE3":1706,"PHASE4":1708,"NA":1721},{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[],{"trials":1705,"activeCount":98},[],{"trials":1707,"activeCount":98},[],{"trials":1709,"activeCount":98},[1710],{"nctId":1711,"briefTitle":1712,"status":108,"phases":1713,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1720},"NCT00813891","Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration",[89],"2009-12","2009-01",180,[1718,1719],"Macular Degeneration","Visual Acuity",[1698,1698,1698],{"trials":1722,"activeCount":98},[],{"intervention":1311,"totalTrials":134,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1731,"PHASE4":1733,"NA":1739},{"trials":1726,"activeCount":98},[],{"trials":1728,"activeCount":98},[],{"trials":1730,"activeCount":98},[],{"trials":1732,"activeCount":98},[],{"trials":1734,"activeCount":98},[1735],{"nctId":1303,"briefTitle":1304,"status":108,"phases":1736,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1208,"conditions":1737,"interventions":1738},[89],[1309],[1279,1311],{"trials":1740,"activeCount":98},[],{"intervention":1742,"totalTrials":134,"cells":1743},"Mebendazole",{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1750,"PHASE4":1752,"NA":1764},{"trials":1745,"activeCount":98},[],{"trials":1747,"activeCount":98},[],{"trials":1749,"activeCount":98},[],{"trials":1751,"activeCount":98},[],{"trials":1753,"activeCount":98},[1754],{"nctId":1755,"briefTitle":1756,"status":462,"phases":1757,"primaryCompletion":1758,"completion":1758,"start":1759,"enrollment":1760,"conditions":1761,"interventions":1763},"NCT01314937","The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas",[89],"2013-07","2011-09",1760,[1762,1668],"Malnutrition",[1742],{"trials":1765,"activeCount":98},[],{"intervention":1767,"totalTrials":134,"cells":1768},"Double dose of Salmeterol + Fluticasone Propionate",{"EARLY_PHASE1":1769,"PHASE1":1771,"PHASE2":1773,"PHASE3":1775,"PHASE4":1777,"NA":1790},{"trials":1770,"activeCount":98},[],{"trials":1772,"activeCount":98},[],{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[],{"trials":1778,"activeCount":98},[1779],{"nctId":1780,"briefTitle":1781,"status":462,"phases":1782,"primaryCompletion":1783,"completion":1783,"start":1784,"enrollment":1785,"conditions":1786,"interventions":1788},"NCT02136875","Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation",[89],"2010-08","2008-07",37,[20,1787],"Chronic Obstructive Pulmonary Disease",[1767,1789],"Self-administered prescription",{"trials":1791,"activeCount":98},[],{"intervention":1789,"totalTrials":134,"cells":1793},{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1800,"PHASE4":1802,"NA":1808},{"trials":1795,"activeCount":98},[],{"trials":1797,"activeCount":98},[],{"trials":1799,"activeCount":98},[],{"trials":1801,"activeCount":98},[],{"trials":1803,"activeCount":98},[1804],{"nctId":1780,"briefTitle":1781,"status":462,"phases":1805,"primaryCompletion":1783,"completion":1783,"start":1784,"enrollment":1785,"conditions":1806,"interventions":1807},[89],[20,1787],[1767,1789],{"trials":1809,"activeCount":98},[],{"intervention":1811,"totalTrials":134,"cells":1812},"lansoprazole",{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1819,"PHASE4":1821,"NA":1834},{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":98},[],{"trials":1822,"activeCount":98},[1823],{"nctId":1824,"briefTitle":1825,"status":108,"phases":1826,"primaryCompletion":449,"completion":1827,"start":1828,"enrollment":8,"conditions":1829,"interventions":1833},"NCT02278081","The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale\u002FBlue Colored Turbinate",[89],"2017-01","2015-01",[1830,1831,1832],"Rhinitis","Nasal Obstruction","GERD",[1811],{"trials":1835,"activeCount":98},[],{"intervention":1837,"totalTrials":134,"cells":1838},"Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block",{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1845,"PHASE4":1847,"NA":1862},{"trials":1840,"activeCount":98},[],{"trials":1842,"activeCount":98},[],{"trials":1844,"activeCount":98},[],{"trials":1846,"activeCount":98},[],{"trials":1848,"activeCount":98},[1849],{"nctId":1850,"briefTitle":1851,"status":108,"phases":1852,"primaryCompletion":1853,"completion":1854,"start":1855,"enrollment":1856,"conditions":1857,"interventions":1860},"NCT04769713","Hepatic Hilar Nerve Block Versus Sham in Pain Control During Liver Ablation and TACE Procedures",[89],"2023-06-30","2023-09-30","2021-11-23",80,[1858,1859],"Pain Control","Liver Cancer",[1837,1861],"Injection of normal saline in the hepatic hilum for the sham procedure",{"trials":1863,"activeCount":98},[],{"intervention":1861,"totalTrials":134,"cells":1865},{"EARLY_PHASE1":1866,"PHASE1":1868,"PHASE2":1870,"PHASE3":1872,"PHASE4":1874,"NA":1880},{"trials":1867,"activeCount":98},[],{"trials":1869,"activeCount":98},[],{"trials":1871,"activeCount":98},[],{"trials":1873,"activeCount":98},[],{"trials":1875,"activeCount":98},[1876],{"nctId":1850,"briefTitle":1851,"status":108,"phases":1877,"primaryCompletion":1853,"completion":1854,"start":1855,"enrollment":1856,"conditions":1878,"interventions":1879},[89],[1858,1859],[1837,1861],{"trials":1881,"activeCount":98},[],{"intervention":1883,"totalTrials":134,"cells":1884},"Sinemet CR",{"EARLY_PHASE1":1885,"PHASE1":1887,"PHASE2":1889,"PHASE3":1891,"PHASE4":1893,"NA":1904},{"trials":1886,"activeCount":98},[],{"trials":1888,"activeCount":98},[],{"trials":1890,"activeCount":98},[],{"trials":1892,"activeCount":98},[],{"trials":1894,"activeCount":98},[1895],{"nctId":1896,"briefTitle":1897,"status":462,"phases":1898,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":747,"conditions":1901,"interventions":1903},"NCT03111485","Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease",[89],"2022-10-28","2017-05-24",[22,1902],"Obstructive Sleep Apnea",[1883],{"trials":1905,"activeCount":98},[],{"intervention":1907,"totalTrials":134,"cells":1908},"HD-TIV",{"EARLY_PHASE1":1909,"PHASE1":1911,"PHASE2":1913,"PHASE3":1915,"PHASE4":1917,"NA":1931},{"trials":1910,"activeCount":98},[],{"trials":1912,"activeCount":98},[],{"trials":1914,"activeCount":98},[],{"trials":1916,"activeCount":98},[],{"trials":1918,"activeCount":98},[1919],{"nctId":1920,"briefTitle":1921,"status":462,"phases":1922,"primaryCompletion":1923,"completion":1924,"start":1925,"enrollment":1926,"conditions":1927,"interventions":1929},"NCT02936180","Standard Versus High Dose Inactivated Influenza Vaccine in RA",[89],"2018-07","2018-12","2016-10",279,[1928],"Rheumatoid Arthritis",[1907,1930],"SD-QIV",{"trials":1932,"activeCount":98},[],{"intervention":1930,"totalTrials":134,"cells":1934},{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1941,"PHASE4":1943,"NA":1949},{"trials":1936,"activeCount":98},[],{"trials":1938,"activeCount":98},[],{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[],{"trials":1944,"activeCount":98},[1945],{"nctId":1920,"briefTitle":1921,"status":462,"phases":1946,"primaryCompletion":1923,"completion":1924,"start":1925,"enrollment":1926,"conditions":1947,"interventions":1948},[89],[1928],[1907,1930],{"trials":1950,"activeCount":98},[],{"intervention":1952,"totalTrials":134,"cells":1953},"Isentress.",{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":1960,"PHASE4":1962,"NA":1975},{"trials":1955,"activeCount":98},[],{"trials":1957,"activeCount":98},[],{"trials":1959,"activeCount":98},[],{"trials":1961,"activeCount":98},[],{"trials":1963,"activeCount":98},[1964],{"nctId":1965,"briefTitle":1966,"status":462,"phases":1967,"primaryCompletion":1968,"completion":1969,"start":1058,"enrollment":1970,"conditions":1971,"interventions":1974},"NCT02210715","Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients",[89],"2019-01-30","2023-01-30",31,[25,1972,1973],"Fatty Liver","Nonalcoholic Steatohepatitis",[1952],{"trials":1976,"activeCount":98},[],{"intervention":1978,"totalTrials":134,"cells":1979},"Moderna COVID-19 vaccine",{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":1986,"PHASE4":2001,"NA":2003},{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":98},[],{"trials":1985,"activeCount":98},[],{"trials":1987,"activeCount":98},[1988],{"nctId":1989,"briefTitle":1990,"status":462,"phases":1991,"primaryCompletion":1992,"completion":1993,"start":1994,"enrollment":1995,"conditions":1996,"interventions":2000},"NCT04806113","COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases",[88],"2021-06-13","2022-06-15","2021-03-11",220,[1997,1998,1928,1999],"Covid19","Rheumatic Diseases","SLE",[1978],{"trials":2002,"activeCount":98},[],{"trials":2004,"activeCount":98},[],{"intervention":2006,"totalTrials":134,"cells":2007},"Various vaccines",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2014,"PHASE4":2024,"NA":2026},{"trials":2009,"activeCount":98},[],{"trials":2011,"activeCount":98},[],{"trials":2013,"activeCount":98},[],{"trials":2015,"activeCount":98},[2016],{"nctId":2017,"briefTitle":2018,"status":2019,"phases":2020,"primaryCompletion":2021,"completion":2021,"start":1715,"enrollment":98,"conditions":2022,"interventions":2023},"NCT00785967","Immune Responses in Patients Treated With Raltegravir","WITHDRAWN",[88],"2011-08",[15],[2006],{"trials":2025,"activeCount":98},[],{"trials":2027,"activeCount":98},[],{"intervention":2029,"totalTrials":134,"cells":2030},"Alendronate",{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2037,"PHASE4":2049,"NA":2051},{"trials":2032,"activeCount":98},[],{"trials":2034,"activeCount":98},[],{"trials":2036,"activeCount":98},[],{"trials":2038,"activeCount":98},[2039],{"nctId":2040,"briefTitle":2041,"status":108,"phases":2042,"completion":2043,"start":2044,"enrollment":2045,"conditions":2046,"interventions":2048},"NCT00346190","The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.",[88],"2007-04","2003-01",10,[2047],"Osteoporosis",[2029],{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[],{"intervention":2054,"totalTrials":134,"cells":2055},"Intrathecal morphine",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2062,"PHASE4":2074,"NA":2076},{"trials":2057,"activeCount":98},[],{"trials":2059,"activeCount":98},[],{"trials":2061,"activeCount":98},[],{"trials":2063,"activeCount":98},[2064],{"nctId":2065,"briefTitle":2066,"status":108,"phases":2067,"primaryCompletion":2068,"completion":2069,"start":1047,"enrollment":2070,"conditions":2071,"interventions":2073},"NCT04256642","Comparison of the Erector Spinae Plane Block Versus Intrathecal Morphine on Post-Cesarean Delivery Analgesia",[88],"2022-01","2023-01",160,[2072],"Cesarean Section Complications",[2054],{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":98},[],{"intervention":2079,"totalTrials":134,"cells":2080},"Fentanyl citrate solution sublingual",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2087,"PHASE4":2099,"NA":2101},{"trials":2082,"activeCount":98},[],{"trials":2084,"activeCount":98},[],{"trials":2086,"activeCount":98},[],{"trials":2088,"activeCount":98},[2089],{"nctId":2090,"briefTitle":2091,"status":1071,"phases":2092,"primaryCompletion":2093,"completion":2094,"start":2095,"enrollment":1691,"conditions":2096,"interventions":2098},"NCT04004117","Effect of Sublingual Fentanyl on Breathlessness in COPD",[87,88],"2019-12-31","2026-02-04","2019-07-01",[2097],"Copd",[2079],{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[],{"intervention":2104,"totalTrials":134,"cells":2105},"oral methadone",{"EARLY_PHASE1":2106,"PHASE1":2108,"PHASE2":2110,"PHASE3":2112,"PHASE4":2125,"NA":2127},{"trials":2107,"activeCount":98},[],{"trials":2109,"activeCount":98},[],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[2114],{"nctId":2115,"briefTitle":2116,"status":108,"phases":2117,"primaryCompletion":2118,"completion":1924,"start":2119,"enrollment":2120,"conditions":2121,"interventions":2123},"NCT02687347","Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic in Cancer Patients With Pain",[88],"2018-02","2016-02",204,[2122],"Pain, Intractable",[2104,2124],"oral morphine",{"trials":2126,"activeCount":98},[],{"trials":2128,"activeCount":98},[],{"intervention":2124,"totalTrials":134,"cells":2130},{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2137,"PHASE4":2143,"NA":2145},{"trials":2132,"activeCount":98},[],{"trials":2134,"activeCount":98},[],{"trials":2136,"activeCount":98},[],{"trials":2138,"activeCount":98},[2139],{"nctId":2115,"briefTitle":2116,"status":108,"phases":2140,"primaryCompletion":2118,"completion":1924,"start":2119,"enrollment":2120,"conditions":2141,"interventions":2142},[88],[2122],[2104,2124],{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[],{"intervention":2148,"totalTrials":134,"cells":2149},"Opioid analgesics",{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2154,"PHASE3":2156,"PHASE4":2172,"NA":2174},{"trials":2151,"activeCount":98},[],{"trials":2153,"activeCount":98},[],{"trials":2155,"activeCount":98},[],{"trials":2157,"activeCount":98},[2158],{"nctId":2159,"briefTitle":2160,"status":462,"phases":2161,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":2165,"conditions":2166,"interventions":2170},"NCT04254679","Pilot Trial: Postoperative Opioid-free Analgesia",[87,88],"2020-09-20","2020-12-03","2020-01-29",81,[2167,2168,2169],"Outpatient Surgery","Abdominal Surgery","Breast Surgery",[2148,2171],"Non-opioid analgesics",{"trials":2173,"activeCount":98},[],{"trials":2175,"activeCount":98},[],{"intervention":2171,"totalTrials":134,"cells":2177},{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2184,"PHASE4":2190,"NA":2192},{"trials":2179,"activeCount":98},[],{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":98},[],{"trials":2185,"activeCount":98},[2186],{"nctId":2159,"briefTitle":2160,"status":462,"phases":2187,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":2165,"conditions":2188,"interventions":2189},[87,88],[2167,2168,2169],[2148,2171],{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":98},[],{"intervention":2195,"totalTrials":134,"cells":2196},"Ketotifen Fumarate",{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2201,"PHASE3":2203,"PHASE4":2214,"NA":2216},{"trials":2198,"activeCount":98},[],{"trials":2200,"activeCount":98},[],{"trials":2202,"activeCount":98},[],{"trials":2204,"activeCount":98},[2205],{"nctId":2206,"briefTitle":2207,"status":462,"phases":2208,"primaryCompletion":1360,"completion":1360,"start":2209,"enrollment":2210,"conditions":2211,"interventions":2213},"NCT02984397","Chronic Widespread Pain and White Blood Cell Activation",[88],"2016-12",44,[2212],"Widespread Chronic Pain",[2195],{"trials":2215,"activeCount":98},[],{"trials":2217,"activeCount":98},[],{"intervention":2219,"totalTrials":134,"cells":2220},"zoledronic acid",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2241,"NA":2243},{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[],{"trials":2228,"activeCount":98},[2229],{"nctId":2230,"briefTitle":2231,"status":462,"phases":2232,"primaryCompletion":2233,"completion":2234,"start":2235,"enrollment":2236,"conditions":2237,"interventions":2240},"NCT00798473","Zoledronate for Osteopenia in Pediatric Crohn's",[88],"2007-09","2008-11","2004-09",13,[2238,2239,2047],"Crohn's Disease","Osteopenia",[2219],{"trials":2242,"activeCount":98},[],{"trials":2244,"activeCount":98},[],{"intervention":2246,"totalTrials":134,"cells":2247},"Caffeine",{"EARLY_PHASE1":2248,"PHASE1":2250,"PHASE2":2252,"PHASE3":2254,"PHASE4":2264,"NA":2266},{"trials":2249,"activeCount":98},[],{"trials":2251,"activeCount":98},[],{"trials":2253,"activeCount":98},[],{"trials":2255,"activeCount":98},[2256],{"nctId":2257,"briefTitle":2258,"status":462,"phases":2259,"primaryCompletion":2260,"completion":1526,"start":1473,"enrollment":2261,"conditions":2262,"interventions":2263},"NCT01738178","Caffeine as a Therapy for Parkinson's Disease",[88],"2016-05-01",119,[22],[2246],{"trials":2265,"activeCount":98},[],{"trials":2267,"activeCount":98},[],{"intervention":2269,"totalTrials":134,"cells":2270},"Morphine",{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2277,"PHASE4":2287,"NA":2289},{"trials":2272,"activeCount":98},[],{"trials":2274,"activeCount":98},[],{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[2279],{"nctId":2280,"briefTitle":2281,"status":108,"phases":2282,"primaryCompletion":2283,"completion":2283,"start":2284,"enrollment":1208,"conditions":2285,"interventions":2286},"NCT01718496","Morphine, Dyspnea, Exercise and COPD",[88],"2016-08","2014-07",[1787],[2269],{"trials":2288,"activeCount":98},[],{"trials":2290,"activeCount":98},[],{"intervention":2292,"totalTrials":134,"cells":2293},"Hydroxychloroquine",{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2298,"PHASE3":2300,"PHASE4":2313,"NA":2315},{"trials":2295,"activeCount":98},[],{"trials":2297,"activeCount":98},[],{"trials":2299,"activeCount":98},[],{"trials":2301,"activeCount":98},[2302],{"nctId":2303,"briefTitle":2304,"status":1071,"phases":2305,"primaryCompletion":2306,"completion":2306,"start":2307,"enrollment":1272,"conditions":2308,"interventions":2312},"NCT04421664","Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)",[88],"2020-08-17","2020-03-25",[2309,2310,2311],"Corona Virus Infection","SARS-CoV Infection","Coronavirus",[2292],{"trials":2314,"activeCount":98},[],{"trials":2316,"activeCount":98},[],{"intervention":2318,"totalTrials":134,"cells":2319},"0.9% saline in 5% dextrose",{"EARLY_PHASE1":2320,"PHASE1":2322,"PHASE2":2324,"PHASE3":2326,"PHASE4":2342,"NA":2344},{"trials":2321,"activeCount":98},[],{"trials":2323,"activeCount":98},[],{"trials":2325,"activeCount":98},[],{"trials":2327,"activeCount":98},[2328],{"nctId":2329,"briefTitle":2330,"status":462,"phases":2331,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2335,"interventions":2340},"NCT00457873","Isotonic Versus Hypotonic Fluid for Maintenance IV Therapy",[88],"2008-04","2007-01",38,[2336,2337,2338,2339],"Gastroenteritis","Bronchiolitis","Sepsis","Urinary Tract Infection",[2318,2341],"0.45% saline in 5% dextrose",{"trials":2343,"activeCount":98},[],{"trials":2345,"activeCount":98},[],{"intervention":2341,"totalTrials":134,"cells":2347},{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2360,"NA":2362},{"trials":2349,"activeCount":98},[],{"trials":2351,"activeCount":98},[],{"trials":2353,"activeCount":98},[],{"trials":2355,"activeCount":98},[2356],{"nctId":2329,"briefTitle":2330,"status":462,"phases":2357,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2358,"interventions":2359},[88],[2336,2337,2338,2339],[2318,2341],{"trials":2361,"activeCount":98},[],{"trials":2363,"activeCount":98},[],{"intervention":2365,"totalTrials":134,"cells":2366},"Sodium bicarbonate",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2386,"NA":2388},{"trials":2368,"activeCount":98},[],{"trials":2370,"activeCount":98},[],{"trials":2372,"activeCount":98},[],{"trials":2374,"activeCount":98},[2375],{"nctId":2376,"briefTitle":2377,"status":108,"phases":2378,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":450,"conditions":2382,"interventions":2384},"NCT00522756","Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy",[88],"2012-12","2013-03","2006-05",[2383],"Kidney Failure, Acute",[2365,2385],"Sodium chloride",{"trials":2387,"activeCount":98},[],{"trials":2389,"activeCount":98},[],{"intervention":2385,"totalTrials":134,"cells":2391},{"EARLY_PHASE1":2392,"PHASE1":2394,"PHASE2":2396,"PHASE3":2398,"PHASE4":2404,"NA":2406},{"trials":2393,"activeCount":98},[],{"trials":2395,"activeCount":98},[],{"trials":2397,"activeCount":98},[],{"trials":2399,"activeCount":98},[2400],{"nctId":2376,"briefTitle":2377,"status":108,"phases":2401,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":450,"conditions":2402,"interventions":2403},[88],[2383],[2365,2385],{"trials":2405,"activeCount":98},[],{"trials":2407,"activeCount":98},[],{"intervention":2409,"totalTrials":134,"cells":2410},"mammalian Omega 3 Fatty acids",{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2417,"PHASE4":2429,"NA":2431},{"trials":2412,"activeCount":98},[],{"trials":2414,"activeCount":98},[],{"trials":2416,"activeCount":98},[],{"trials":2418,"activeCount":98},[2419],{"nctId":2420,"briefTitle":2421,"status":108,"phases":2422,"primaryCompletion":1472,"completion":2423,"start":1828,"enrollment":2424,"conditions":2425,"interventions":2428},"NCT02294149","Vit D3 and Omega 3 in Chemo Induced Neuropathy",[88],"2016-11",600,[2426,2427],"Cancer","Neuropathy",[2409],{"trials":2430,"activeCount":98},[],{"trials":2432,"activeCount":98},[],{"intervention":2434,"totalTrials":134,"cells":2435},"Aspirin",{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2440,"PHASE3":2442,"PHASE4":2456,"NA":2458},{"trials":2437,"activeCount":98},[],{"trials":2439,"activeCount":98},[],{"trials":2441,"activeCount":98},[],{"trials":2443,"activeCount":98},[2444],{"nctId":2445,"briefTitle":2446,"status":108,"phases":2447,"primaryCompletion":2448,"completion":2449,"start":2450,"enrollment":2451,"conditions":2452,"interventions":2455},"NCT03405974","Aspirin in the Prevention of Collapse in Osteonecrosis of the Hip",[88],"2020-11-01","2021-11-01","2017-10-12",114,[2453,2454],"Osteonecrosis of Femoral Head","Osteonecrosis; Aseptic, Idiopathic",[2434],{"trials":2457,"activeCount":98},[],{"trials":2459,"activeCount":98},[],{"intervention":2461,"totalTrials":134,"cells":2462},"Rosuvastatin",{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2467,"PHASE3":2469,"PHASE4":2480,"NA":2482},{"trials":2464,"activeCount":98},[],{"trials":2466,"activeCount":98},[],{"trials":2468,"activeCount":98},[],{"trials":2470,"activeCount":98},[2471],{"nctId":2472,"briefTitle":2473,"status":462,"phases":2474,"primaryCompletion":2475,"completion":2475,"start":2476,"enrollment":478,"conditions":2477,"interventions":2479},"NCT01425398","A Trial to Evaluate the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery",[88],"2013-12","2011-11",[2478],"Valvular Cardiac Surgery",[2461],{"trials":2481,"activeCount":98},[],{"trials":2483,"activeCount":98},[],{"intervention":2485,"totalTrials":134,"cells":2486},"Dapsone 85 mg PO BID",{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2493,"PHASE4":2506,"NA":2508},{"trials":2488,"activeCount":98},[],{"trials":2490,"activeCount":98},[],{"trials":2492,"activeCount":98},[],{"trials":2494,"activeCount":98},[2495],{"nctId":2496,"briefTitle":2497,"status":108,"phases":2498,"primaryCompletion":2499,"completion":2500,"start":2501,"enrollment":2502,"conditions":2503,"interventions":2505},"NCT04935476","Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19",[88],"2022-03-31","2022-07-31","2021-11-22",3000,[2504],"COVID-19",[2485],{"trials":2507,"activeCount":98},[],{"trials":2509,"activeCount":98},[],{"intervention":2511,"totalTrials":134,"cells":2512},"Normal Saline intranasal and placebo inhaler",{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2517,"PHASE3":2519,"PHASE4":2533,"NA":2535},{"trials":2514,"activeCount":98},[],{"trials":2516,"activeCount":98},[],{"trials":2518,"activeCount":98},[],{"trials":2520,"activeCount":98},[2521],{"nctId":2522,"briefTitle":2523,"status":1071,"phases":2524,"primaryCompletion":2525,"completion":2526,"start":2527,"enrollment":2528,"conditions":2529,"interventions":2530},"NCT04435795","Inhaled Ciclesonide for Outpatients With COVID19",[87,88],"2021-06-08","2021-07-08","2020-09-15",215,[875],[2511,2531,2532],"Ciclesonide","Ciclesonide nasal",{"trials":2534,"activeCount":98},[],{"trials":2536,"activeCount":98},[],{"intervention":2531,"totalTrials":134,"cells":2538},{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2545,"PHASE4":2551,"NA":2553},{"trials":2540,"activeCount":98},[],{"trials":2542,"activeCount":98},[],{"trials":2544,"activeCount":98},[],{"trials":2546,"activeCount":98},[2547],{"nctId":2522,"briefTitle":2523,"status":1071,"phases":2548,"primaryCompletion":2525,"completion":2526,"start":2527,"enrollment":2528,"conditions":2549,"interventions":2550},[87,88],[875],[2511,2531,2532],{"trials":2552,"activeCount":98},[],{"trials":2554,"activeCount":98},[],{"intervention":2532,"totalTrials":134,"cells":2556},{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2563,"PHASE4":2569,"NA":2571},{"trials":2558,"activeCount":98},[],{"trials":2560,"activeCount":98},[],{"trials":2562,"activeCount":98},[],{"trials":2564,"activeCount":98},[2565],{"nctId":2522,"briefTitle":2523,"status":1071,"phases":2566,"primaryCompletion":2525,"completion":2526,"start":2527,"enrollment":2528,"conditions":2567,"interventions":2568},[87,88],[875],[2511,2531,2532],{"trials":2570,"activeCount":98},[],{"trials":2572,"activeCount":98},[],{"intervention":2574,"totalTrials":134,"cells":2575},"basiliximab",{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2591,"NA":2593},{"trials":2577,"activeCount":98},[],{"trials":2579,"activeCount":98},[],{"trials":2581,"activeCount":98},[],{"trials":2583,"activeCount":98},[2584],{"nctId":2585,"briefTitle":2586,"status":108,"phases":2587,"completion":2332,"start":2043,"enrollment":336,"conditions":2588,"interventions":2590},"NCT00302497","EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function",[88],[2589],"Kidney Transplant",[2574],{"trials":2592,"activeCount":98},[],{"trials":2594,"activeCount":98},[],{"intervention":2596,"totalTrials":134,"cells":2597},"Aclidinium bromide\u002Fformoterol fumarate dihydrate",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2604,"PHASE4":2617,"NA":2619},{"trials":2599,"activeCount":98},[],{"trials":2601,"activeCount":98},[],{"trials":2603,"activeCount":98},[],{"trials":2605,"activeCount":98},[2606],{"nctId":2607,"briefTitle":2608,"status":462,"phases":2609,"primaryCompletion":2610,"completion":2611,"start":2612,"enrollment":2613,"conditions":2614,"interventions":2616},"NCT03104634","The Effects of Inhaled Aclidinium Bromide\u002FFormoterol Fumarate on Inspiratory Pleural Pressures in Smokers",[88],"2018-12-01","2019-02-01","2017-05-01",43,[2615],"Smoking",[2596],{"trials":2618,"activeCount":98},[],{"trials":2620,"activeCount":98},[],{"intervention":2622,"totalTrials":134,"cells":2623},"Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy",{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2628,"PHASE3":2630,"PHASE4":2642,"NA":2644},{"trials":2625,"activeCount":98},[],{"trials":2627,"activeCount":98},[],{"trials":2629,"activeCount":98},[],{"trials":2631,"activeCount":98},[2632],{"nctId":2633,"briefTitle":2634,"status":462,"phases":2635,"primaryCompletion":2636,"completion":2637,"start":2638,"enrollment":2639,"conditions":2640,"interventions":2641},"NCT05205928","Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care",[87,88],"2024-04-15","2024-06-30","2022-10-02",28,[18,27],[2622],{"trials":2643,"activeCount":98},[],{"trials":2645,"activeCount":98},[],{"intervention":595,"totalTrials":134,"cells":2647},{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2660,"NA":2662},{"trials":2649,"activeCount":98},[],{"trials":2651,"activeCount":98},[],{"trials":2653,"activeCount":98},[],{"trials":2655,"activeCount":98},[2656],{"nctId":585,"briefTitle":586,"status":462,"phases":2657,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":2658,"interventions":2659},[88],[593],[562,595],{"trials":2661,"activeCount":98},[],{"trials":2663,"activeCount":98},[],{"intervention":2665,"totalTrials":134,"cells":2666},"Lyumjev",{"EARLY_PHASE1":2667,"PHASE1":2669,"PHASE2":2671,"PHASE3":2673,"PHASE4":2685,"NA":2687},{"trials":2668,"activeCount":98},[],{"trials":2670,"activeCount":98},[],{"trials":2672,"activeCount":98},[],{"trials":2674,"activeCount":98},[2675],{"nctId":2676,"briefTitle":2677,"status":108,"phases":2678,"primaryCompletion":746,"completion":2679,"start":2680,"enrollment":963,"conditions":2681,"interventions":2683},"NCT06046417","A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes",[87,88],"2025-06","2023-11-30",[2682,27],"type1diabetes",[2684,2665],"Pramlintide",{"trials":2686,"activeCount":98},[],{"trials":2688,"activeCount":98},[],{"intervention":2690,"totalTrials":134,"cells":2691},"Myfortic",{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2698,"PHASE4":2708,"NA":2710},{"trials":2693,"activeCount":98},[],{"trials":2695,"activeCount":98},[],{"trials":2697,"activeCount":98},[],{"trials":2699,"activeCount":98},[2700],{"nctId":2701,"briefTitle":2702,"status":108,"phases":2703,"primaryCompletion":1714,"completion":1714,"start":2704,"enrollment":492,"conditions":2705,"interventions":2707},"NCT00468936","Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms",[88],"2007-05",[2706],"Heart Transplant Patients",[2690],{"trials":2709,"activeCount":98},[],{"trials":2711,"activeCount":98},[],{"intervention":2713,"totalTrials":134,"cells":2714},"Betaine",{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2721,"PHASE4":2732,"NA":2734},{"trials":2716,"activeCount":98},[],{"trials":2718,"activeCount":98},[],{"trials":2720,"activeCount":98},[],{"trials":2722,"activeCount":98},[2723],{"nctId":2724,"briefTitle":2725,"status":462,"phases":2726,"primaryCompletion":1828,"completion":2727,"start":2380,"enrollment":2728,"conditions":2729,"interventions":2731},"NCT01838941","Betaine and Peroxisome Biogenesis Disorders",[88],"2015-06",12,[2730],"Peroxisome Biogenesis Disorders",[2713],{"trials":2733,"activeCount":98},[],{"trials":2735,"activeCount":98},[],{"intervention":2737,"totalTrials":134,"cells":2738},"2 ml bupivacaine",{"EARLY_PHASE1":2739,"PHASE1":2741,"PHASE2":2743,"PHASE3":2756,"PHASE4":2758,"NA":2760},{"trials":2740,"activeCount":98},[],{"trials":2742,"activeCount":98},[],{"trials":2744,"activeCount":98},[2745],{"nctId":2746,"briefTitle":2747,"status":462,"phases":2748,"primaryCompletion":2749,"completion":2750,"start":2751,"enrollment":336,"conditions":2752,"interventions":2754},"NCT01561274","ET 50 for Post Caesarean Section Spinal Hypotension",[87],"2014-03","2014-05","2012-03",[2753],"Hypotension",[2737,2755],"1.5 ml bupivicaine.",{"trials":2757,"activeCount":98},[],{"trials":2759,"activeCount":98},[],{"trials":2761,"activeCount":98},[],{"intervention":2755,"totalTrials":134,"cells":2763},{"EARLY_PHASE1":2764,"PHASE1":2766,"PHASE2":2768,"PHASE3":2774,"PHASE4":2776,"NA":2778},{"trials":2765,"activeCount":98},[],{"trials":2767,"activeCount":98},[],{"trials":2769,"activeCount":98},[2770],{"nctId":2746,"briefTitle":2747,"status":462,"phases":2771,"primaryCompletion":2749,"completion":2750,"start":2751,"enrollment":336,"conditions":2772,"interventions":2773},[87],[2753],[2737,2755],{"trials":2775,"activeCount":98},[],{"trials":2777,"activeCount":98},[],{"trials":2779,"activeCount":98},[],{"intervention":2781,"totalTrials":134,"cells":2782},"TN-TC11M2 oral",{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2787,"PHASE3":2798,"PHASE4":2800,"NA":2802},{"trials":2784,"activeCount":98},[],{"trials":2786,"activeCount":98},[],{"trials":2788,"activeCount":98},[2789],{"nctId":2790,"briefTitle":2791,"status":1071,"phases":2792,"primaryCompletion":2793,"completion":2793,"start":2794,"enrollment":2045,"conditions":2795,"interventions":2796},"NCT03550352","Cannabinoids in PLWHIV on Effective ART",[87],"2022-05-31","2021-08-20",[15],[2781,2797],"TN-C200M2 oral",{"trials":2799,"activeCount":98},[],{"trials":2801,"activeCount":98},[],{"trials":2803,"activeCount":98},[],{"intervention":2797,"totalTrials":134,"cells":2805},{"EARLY_PHASE1":2806,"PHASE1":2808,"PHASE2":2810,"PHASE3":2816,"PHASE4":2818,"NA":2820},{"trials":2807,"activeCount":98},[],{"trials":2809,"activeCount":98},[],{"trials":2811,"activeCount":98},[2812],{"nctId":2790,"briefTitle":2791,"status":1071,"phases":2813,"primaryCompletion":2793,"completion":2793,"start":2794,"enrollment":2045,"conditions":2814,"interventions":2815},[87],[15],[2781,2797],{"trials":2817,"activeCount":98},[],{"trials":2819,"activeCount":98},[],{"trials":2821,"activeCount":98},[],{"intervention":2823,"totalTrials":134,"cells":2824},"N-acetylcysteine",{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2829,"PHASE3":2841,"PHASE4":2843,"NA":2845},{"trials":2826,"activeCount":98},[],{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[2831],{"nctId":2832,"briefTitle":2833,"status":462,"phases":2834,"primaryCompletion":2835,"completion":2836,"start":2837,"enrollment":30,"conditions":2838,"interventions":2840},"NCT00483314","Homocystinuria: Treatment With N-Acetylcysteine",[87],"2008-12","2009-02","2007-11",[2839],"Homocystinuria",[2823],{"trials":2842,"activeCount":98},[],{"trials":2844,"activeCount":98},[],{"trials":2846,"activeCount":98},[],{"intervention":2848,"totalTrials":134,"cells":2849},"Allogeneic Wharton's jelly-MSCs",{"EARLY_PHASE1":2850,"PHASE1":2852,"PHASE2":2854,"PHASE3":2865,"PHASE4":2867,"NA":2869},{"trials":2851,"activeCount":98},[],{"trials":2853,"activeCount":98},[],{"trials":2855,"activeCount":98},[2856],{"nctId":2857,"briefTitle":2858,"status":1071,"phases":2859,"primaryCompletion":2860,"completion":2860,"start":2861,"enrollment":2862,"conditions":2863,"interventions":2864},"NCT04869397","Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells",[87],"2023-05-26","2021-06-14",19,[1997],[2848],{"trials":2866,"activeCount":98},[],{"trials":2868,"activeCount":98},[],{"trials":2870,"activeCount":98},[],{"intervention":2872,"totalTrials":134,"cells":2873},"Somatotropin",{"EARLY_PHASE1":2874,"PHASE1":2876,"PHASE2":2878,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2875,"activeCount":98},[],{"trials":2877,"activeCount":98},[],{"trials":2879,"activeCount":98},[2880],{"nctId":2881,"briefTitle":2882,"status":462,"phases":2883,"primaryCompletion":2884,"completion":1206,"start":2209,"enrollment":1049,"conditions":2885,"interventions":2888},"NCT03091374","Impact of Recombinant Human Growth Hormone on HIV Persistence",[87],"2021-03",[2886,2887],"Human Immunodeficiency Virus","Growth Hormone Treatment",[2872],{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[],{"trials":2894,"activeCount":98},[],{"intervention":2896,"totalTrials":134,"cells":2897},"mDCF + Avelumab",{"EARLY_PHASE1":2898,"PHASE1":2900,"PHASE2":2902,"PHASE3":2916,"PHASE4":2918,"NA":2920},{"trials":2899,"activeCount":98},[],{"trials":2901,"activeCount":98},[],{"trials":2903,"activeCount":98},[2904],{"nctId":2905,"briefTitle":2906,"status":108,"phases":2907,"primaryCompletion":2908,"completion":2909,"start":2910,"enrollment":2911,"conditions":2912,"interventions":2915},"NCT03288350","mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)",[87],"2020-12","2023-12","2018-02-22",55,[2913,2914],"Gastric Adenocarcinoma","Esophageal Adenocarcinoma",[2896],{"trials":2917,"activeCount":98},[],{"trials":2919,"activeCount":98},[],{"trials":2921,"activeCount":98},[],{"intervention":2923,"totalTrials":134,"cells":2924},"Raltegravir",{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2943,"PHASE4":2945,"NA":2947},{"trials":2926,"activeCount":98},[],{"trials":2928,"activeCount":98},[],{"trials":2930,"activeCount":98},[2931],{"nctId":2932,"briefTitle":2933,"status":462,"phases":2934,"primaryCompletion":2935,"completion":1048,"start":2936,"enrollment":2937,"conditions":2938,"interventions":2941},"NCT01231685","Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection",[87],"2016-03","2011-12",9,[25,2939,2940],"Hepatitis C","Liver Fibrosis",[2923,2942],"Ritonavir-boosted protease inhibitor",{"trials":2944,"activeCount":98},[],{"trials":2946,"activeCount":98},[],{"trials":2948,"activeCount":98},[],{"intervention":2942,"totalTrials":134,"cells":2950},{"EARLY_PHASE1":2951,"PHASE1":2953,"PHASE2":2955,"PHASE3":2961,"PHASE4":2963,"NA":2965},{"trials":2952,"activeCount":98},[],{"trials":2954,"activeCount":98},[],{"trials":2956,"activeCount":98},[2957],{"nctId":2932,"briefTitle":2933,"status":462,"phases":2958,"primaryCompletion":2935,"completion":1048,"start":2936,"enrollment":2937,"conditions":2959,"interventions":2960},[87],[25,2939,2940],[2923,2942],{"trials":2962,"activeCount":98},[],{"trials":2964,"activeCount":98},[],{"trials":2966,"activeCount":98},[],{"intervention":2968,"totalTrials":134,"cells":2969},"Ethosuximide",{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2974,"PHASE3":2985,"PHASE4":2987,"NA":2989},{"trials":2971,"activeCount":98},[],{"trials":2973,"activeCount":98},[],{"trials":2975,"activeCount":98},[2976],{"nctId":2977,"briefTitle":2978,"status":1071,"phases":2979,"primaryCompletion":2980,"completion":2980,"start":2981,"enrollment":435,"conditions":2982,"interventions":2984},"NCT00689585","Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)",[87],"2010-07","2008-09",[2983],"Complex Regional Pain Syndromes",[2968],{"trials":2986,"activeCount":98},[],{"trials":2988,"activeCount":98},[],{"trials":2990,"activeCount":98},[],{"intervention":2992,"totalTrials":134,"cells":2993},"Bupivacaine with 15 micrograms of fentanyl",{"EARLY_PHASE1":2994,"PHASE1":2996,"PHASE2":2998,"PHASE3":3007,"PHASE4":3009,"NA":3011},{"trials":2995,"activeCount":98},[],{"trials":2997,"activeCount":98},[],{"trials":2999,"activeCount":98},[3000],{"nctId":3001,"briefTitle":3002,"status":108,"phases":3003,"primaryCompletion":2727,"completion":2727,"start":1758,"enrollment":1691,"conditions":3004,"interventions":3006},"NCT01896960","ET50 With Fentanyl for Post Caesarean Section Spinal Hypotension",[87],[2753,3005],"Pregnancy",[2992],{"trials":3008,"activeCount":98},[],{"trials":3010,"activeCount":98},[],{"trials":3012,"activeCount":98},[],{"intervention":3014,"totalTrials":134,"cells":3015},"Atezolizumab",{"EARLY_PHASE1":3016,"PHASE1":3018,"PHASE2":3020,"PHASE3":3032,"PHASE4":3034,"NA":3036},{"trials":3017,"activeCount":98},[],{"trials":3019,"activeCount":98},[],{"trials":3021,"activeCount":98},[3022],{"nctId":3023,"briefTitle":3024,"status":108,"phases":3025,"primaryCompletion":3026,"completion":3027,"start":3028,"enrollment":1500,"conditions":3029,"interventions":3031},"NCT03620435","Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer",[87],"2020-05-30","2020-12-30","2018-05-01",[3030],"Safety Issues",[3014],{"trials":3033,"activeCount":98},[],{"trials":3035,"activeCount":98},[],{"trials":3037,"activeCount":98},[],{"intervention":3039,"totalTrials":134,"cells":3040},"Lactated Ringer's Solution",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3058,"PHASE4":3060,"NA":3062},{"trials":3042,"activeCount":98},[],{"trials":3044,"activeCount":98},[],{"trials":3046,"activeCount":98},[3047],{"nctId":3048,"briefTitle":3049,"status":108,"phases":3050,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":1089,"conditions":3054,"interventions":3057},"NCT01236833","Lactated Ringer's Solution in Neonates With Feeding Intolerance",[87],"2012-06","2012-09","2010-11",[3055,3056],"Intestinal Disease","Feeding Disorder Neonatal",[3039],{"trials":3059,"activeCount":98},[],{"trials":3061,"activeCount":98},[],{"trials":3063,"activeCount":98},[],{"intervention":3065,"totalTrials":134,"cells":3066},"Omalizumab",{"EARLY_PHASE1":3067,"PHASE1":3069,"PHASE2":3071,"PHASE3":3082,"PHASE4":3084,"NA":3086},{"trials":3068,"activeCount":98},[],{"trials":3070,"activeCount":98},[],{"trials":3072,"activeCount":98},[3073],{"nctId":3074,"briefTitle":3075,"status":108,"phases":3076,"primaryCompletion":3077,"completion":3078,"start":3079,"enrollment":1691,"conditions":3080,"interventions":3081},"NCT04720612","COVID-19 Immunologic Antiviral Therapy With Omalizumab",[87],"2022-11-07","2022-12-16","2021-10-15",[1997],[3065],{"trials":3083,"activeCount":98},[],{"trials":3085,"activeCount":98},[],{"trials":3087,"activeCount":98},[],{"intervention":3089,"totalTrials":134,"cells":3090},"Propranolol PO",{"EARLY_PHASE1":3091,"PHASE1":3093,"PHASE2":3095,"PHASE3":3107,"PHASE4":3109,"NA":3111},{"trials":3092,"activeCount":98},[],{"trials":3094,"activeCount":98},[],{"trials":3096,"activeCount":98},[3097],{"nctId":3098,"briefTitle":3099,"status":1071,"phases":3100,"primaryCompletion":3101,"completion":3101,"start":3102,"enrollment":2045,"conditions":3103,"interventions":3104},"NCT02511483","Genetic Predictors of Analgesic Efficacy of Propranolol for Treating Postoperative Pain",[87],"2016-11-12","2015-05-18",[32],[3089,3105,3106],"IV-PCA morphine","COMT-haplotypes",{"trials":3108,"activeCount":98},[],{"trials":3110,"activeCount":98},[],{"trials":3112,"activeCount":98},[],{"intervention":3105,"totalTrials":134,"cells":3114},{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3119,"PHASE3":3125,"PHASE4":3127,"NA":3129},{"trials":3116,"activeCount":98},[],{"trials":3118,"activeCount":98},[],{"trials":3120,"activeCount":98},[3121],{"nctId":3098,"briefTitle":3099,"status":1071,"phases":3122,"primaryCompletion":3101,"completion":3101,"start":3102,"enrollment":2045,"conditions":3123,"interventions":3124},[87],[32],[3089,3105,3106],{"trials":3126,"activeCount":98},[],{"trials":3128,"activeCount":98},[],{"trials":3130,"activeCount":98},[],{"intervention":3106,"totalTrials":134,"cells":3132},{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3143,"PHASE4":3145,"NA":3147},{"trials":3134,"activeCount":98},[],{"trials":3136,"activeCount":98},[],{"trials":3138,"activeCount":98},[3139],{"nctId":3098,"briefTitle":3099,"status":1071,"phases":3140,"primaryCompletion":3101,"completion":3101,"start":3102,"enrollment":2045,"conditions":3141,"interventions":3142},[87],[32],[3089,3105,3106],{"trials":3144,"activeCount":98},[],{"trials":3146,"activeCount":98},[],{"trials":3148,"activeCount":98},[],{"intervention":540,"totalTrials":134,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3152,"activeCount":98},[],{"trials":3154,"activeCount":98},[],{"trials":3156,"activeCount":98},[3157],{"nctId":529,"briefTitle":530,"status":462,"phases":3158,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":3159,"interventions":3160},[87],[537],[539,540,541],{"trials":3162,"activeCount":98},[],{"trials":3164,"activeCount":98},[],{"trials":3166,"activeCount":98},[],{"intervention":541,"totalTrials":134,"cells":3168},{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3179,"PHASE4":3181,"NA":3183},{"trials":3170,"activeCount":98},[],{"trials":3172,"activeCount":98},[],{"trials":3174,"activeCount":98},[3175],{"nctId":529,"briefTitle":530,"status":462,"phases":3176,"primaryCompletion":532,"completion":533,"start":534,"enrollment":535,"conditions":3177,"interventions":3178},[87],[537],[539,540,541],{"trials":3180,"activeCount":98},[],{"trials":3182,"activeCount":98},[],{"trials":3184,"activeCount":98},[],{"intervention":3186,"totalTrials":134,"cells":3187},"Hybrid automated Lyumjev delivery system with carbohydrate counting",{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3192,"PHASE3":3203,"PHASE4":3205,"NA":3207},{"trials":3189,"activeCount":98},[],{"trials":3191,"activeCount":98},[],{"trials":3193,"activeCount":98},[3194],{"nctId":3195,"briefTitle":3196,"status":108,"phases":3197,"primaryCompletion":1206,"completion":1206,"start":3198,"enrollment":2728,"conditions":3199,"interventions":3200},"NCT06021158","A Trial to Compare Automated Lyumjev Delivery With Carbohydrate Counting, Qualitative Meal-size Estimation, and Meal Detection in Type 1 Diabetes",[87],"2023-12-20",[27,18],[3186,3201,3202],"Hybrid automated Lyumjev delivery system with meal size estimation","Fully automated Lyumjev delivery system with meal detection",{"trials":3204,"activeCount":98},[],{"trials":3206,"activeCount":98},[],{"trials":3208,"activeCount":98},[],{"intervention":3201,"totalTrials":134,"cells":3210},{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3215,"PHASE3":3221,"PHASE4":3223,"NA":3225},{"trials":3212,"activeCount":98},[],{"trials":3214,"activeCount":98},[],{"trials":3216,"activeCount":98},[3217],{"nctId":3195,"briefTitle":3196,"status":108,"phases":3218,"primaryCompletion":1206,"completion":1206,"start":3198,"enrollment":2728,"conditions":3219,"interventions":3220},[87],[27,18],[3186,3201,3202],{"trials":3222,"activeCount":98},[],{"trials":3224,"activeCount":98},[],{"trials":3226,"activeCount":98},[],{"intervention":3202,"totalTrials":134,"cells":3228},{"EARLY_PHASE1":3229,"PHASE1":3231,"PHASE2":3233,"PHASE3":3239,"PHASE4":3241,"NA":3243},{"trials":3230,"activeCount":98},[],{"trials":3232,"activeCount":98},[],{"trials":3234,"activeCount":98},[3235],{"nctId":3195,"briefTitle":3196,"status":108,"phases":3236,"primaryCompletion":1206,"completion":1206,"start":3198,"enrollment":2728,"conditions":3237,"interventions":3238},[87],[27,18],[3186,3201,3202],{"trials":3240,"activeCount":98},[],{"trials":3242,"activeCount":98},[],{"trials":3244,"activeCount":98},[],{"intervention":3246,"totalTrials":134,"cells":3247},"Niacin",{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3252,"PHASE3":3261,"PHASE4":3263,"NA":3265},{"trials":3249,"activeCount":98},[],{"trials":3251,"activeCount":98},[],{"trials":3253,"activeCount":98},[3254],{"nctId":3255,"briefTitle":3256,"status":462,"phases":3257,"primaryCompletion":447,"completion":447,"start":2476,"enrollment":3258,"conditions":3259,"interventions":3260},"NCT02018965","Niacin on Immune Activation : a Proof-of-concept Study",[87],16,[25],[3246,3246],{"trials":3262,"activeCount":98},[],{"trials":3264,"activeCount":98},[],{"trials":3266,"activeCount":98},[],{"intervention":3268,"totalTrials":134,"cells":3269},"0.75% Ropivacaine",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3274,"PHASE3":3285,"PHASE4":3287,"NA":3289},{"trials":3271,"activeCount":98},[],{"trials":3273,"activeCount":98},[],{"trials":3275,"activeCount":98},[3276],{"nctId":3277,"briefTitle":3278,"status":462,"phases":3279,"primaryCompletion":3280,"completion":3280,"start":1472,"enrollment":2210,"conditions":3281,"interventions":3283},"NCT02270255","Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization",[87],"2017-11-01",[3282],"Leiomyoma",[3268,3284],"1% Xylocaine",{"trials":3286,"activeCount":98},[],{"trials":3288,"activeCount":98},[],{"trials":3290,"activeCount":98},[],{"intervention":3284,"totalTrials":134,"cells":3292},{"EARLY_PHASE1":3293,"PHASE1":3295,"PHASE2":3297,"PHASE3":3303,"PHASE4":3305,"NA":3307},{"trials":3294,"activeCount":98},[],{"trials":3296,"activeCount":98},[],{"trials":3298,"activeCount":98},[3299],{"nctId":3277,"briefTitle":3278,"status":462,"phases":3300,"primaryCompletion":3280,"completion":3280,"start":1472,"enrollment":2210,"conditions":3301,"interventions":3302},[87],[3282],[3268,3284],{"trials":3304,"activeCount":98},[],{"trials":3306,"activeCount":98},[],{"trials":3308,"activeCount":98},[],{"intervention":3310,"totalTrials":134,"cells":3311},"Spinal analgesia",{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3328,"PHASE4":3330,"NA":3332},{"trials":3313,"activeCount":98},[],{"trials":3315,"activeCount":98},[],{"trials":3317,"activeCount":98},[3318],{"nctId":3319,"briefTitle":3320,"status":462,"phases":3321,"primaryCompletion":1306,"completion":1306,"start":1448,"enrollment":1691,"conditions":3322,"interventions":3326},"NCT01477190","Spinal Analgesia for Colonic Resection Using an Enhanced Recovery After Surgery (ERAS) Program",[86,87],[3323,3324,3325],"Colon Cancer","Inflammatory Bowel Diseases","Diverticulitis",[3310,3327],"Patient Control Analgesia (PCA) Morphine",{"trials":3329,"activeCount":98},[],{"trials":3331,"activeCount":98},[],{"trials":3333,"activeCount":98},[],{"intervention":3327,"totalTrials":134,"cells":3335},{"EARLY_PHASE1":3336,"PHASE1":3338,"PHASE2":3340,"PHASE3":3346,"PHASE4":3348,"NA":3350},{"trials":3337,"activeCount":98},[],{"trials":3339,"activeCount":98},[],{"trials":3341,"activeCount":98},[3342],{"nctId":3319,"briefTitle":3320,"status":462,"phases":3343,"primaryCompletion":1306,"completion":1306,"start":1448,"enrollment":1691,"conditions":3344,"interventions":3345},[86,87],[3323,3324,3325],[3310,3327],{"trials":3347,"activeCount":98},[],{"trials":3349,"activeCount":98},[],{"trials":3351,"activeCount":98},[],{"intervention":3353,"totalTrials":134,"cells":3354},"Pembrolizumab",{"EARLY_PHASE1":3355,"PHASE1":3357,"PHASE2":3359,"PHASE3":3373,"PHASE4":3375,"NA":3377},{"trials":3356,"activeCount":98},[],{"trials":3358,"activeCount":98},[],{"trials":3360,"activeCount":98},[3361],{"nctId":3362,"briefTitle":3363,"status":1071,"phases":3364,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":23,"conditions":3367,"interventions":3369},"NCT04638582","Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)",[87],"2026-04-14","2022-08-28",[3368],"Lung Cancer, Nonsmall Cell",[3353,3370,3371,3372],"Carboplatin","Paclitaxel","Pemetrexed",{"trials":3374,"activeCount":98},[],{"trials":3376,"activeCount":98},[],{"trials":3378,"activeCount":98},[],{"intervention":3370,"totalTrials":134,"cells":3380},{"EARLY_PHASE1":3381,"PHASE1":3383,"PHASE2":3385,"PHASE3":3391,"PHASE4":3393,"NA":3395},{"trials":3382,"activeCount":98},[],{"trials":3384,"activeCount":98},[],{"trials":3386,"activeCount":98},[3387],{"nctId":3362,"briefTitle":3363,"status":1071,"phases":3388,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":23,"conditions":3389,"interventions":3390},[87],[3368],[3353,3370,3371,3372],{"trials":3392,"activeCount":98},[],{"trials":3394,"activeCount":98},[],{"trials":3396,"activeCount":98},[],{"intervention":3371,"totalTrials":134,"cells":3398},{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3409,"PHASE4":3411,"NA":3413},{"trials":3400,"activeCount":98},[],{"trials":3402,"activeCount":98},[],{"trials":3404,"activeCount":98},[3405],{"nctId":3362,"briefTitle":3363,"status":1071,"phases":3406,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":23,"conditions":3407,"interventions":3408},[87],[3368],[3353,3370,3371,3372],{"trials":3410,"activeCount":98},[],{"trials":3412,"activeCount":98},[],{"trials":3414,"activeCount":98},[],{"intervention":3372,"totalTrials":134,"cells":3416},{"EARLY_PHASE1":3417,"PHASE1":3419,"PHASE2":3421,"PHASE3":3427,"PHASE4":3429,"NA":3431},{"trials":3418,"activeCount":98},[],{"trials":3420,"activeCount":98},[],{"trials":3422,"activeCount":98},[3423],{"nctId":3362,"briefTitle":3363,"status":1071,"phases":3424,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":23,"conditions":3425,"interventions":3426},[87],[3368],[3353,3370,3371,3372],{"trials":3428,"activeCount":98},[],{"trials":3430,"activeCount":98},[],{"trials":3432,"activeCount":98},[],{"intervention":3434,"totalTrials":134,"cells":3435},"AGS-004",{"EARLY_PHASE1":3436,"PHASE1":3438,"PHASE2":3440,"PHASE3":3452,"PHASE4":3454,"NA":3456},{"trials":3437,"activeCount":98},[],{"trials":3439,"activeCount":98},[],{"trials":3441,"activeCount":98},[3442],{"nctId":3443,"briefTitle":3444,"status":462,"phases":3445,"primaryCompletion":3446,"completion":2234,"start":3447,"enrollment":2045,"conditions":3448,"interventions":3451},"NCT00381212","A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.",[86,87],"2008-02","2006-09",[3449,3450],"HIV Seropositivity","Acquired Immunodeficiency Syndrome",[3434],{"trials":3453,"activeCount":98},[],{"trials":3455,"activeCount":98},[],{"trials":3457,"activeCount":98},[],{"intervention":3459,"totalTrials":134,"cells":3460},"Ringer's Lactate",{"EARLY_PHASE1":3461,"PHASE1":3463,"PHASE2":3465,"PHASE3":3475,"PHASE4":3477,"NA":3479},{"trials":3462,"activeCount":98},[],{"trials":3464,"activeCount":98},[],{"trials":3466,"activeCount":98},[3467],{"nctId":3468,"briefTitle":3469,"status":108,"phases":3470,"primaryCompletion":3471,"start":2332,"enrollment":1208,"conditions":3472,"interventions":3474},"NCT01108601","Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity",[86,87],"2011-04",[3473],"Hearing Loss",[3459],{"trials":3476,"activeCount":98},[],{"trials":3478,"activeCount":98},[],{"trials":3480,"activeCount":98},[],{"intervention":3482,"totalTrials":134,"cells":3483},"rhDNase I",{"EARLY_PHASE1":3484,"PHASE1":3486,"PHASE2":3499,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3485,"activeCount":98},[],{"trials":3487,"activeCount":98},[3488],{"nctId":3489,"briefTitle":3490,"status":462,"phases":3491,"primaryCompletion":3492,"completion":3493,"start":3494,"enrollment":3495,"conditions":3496,"interventions":3498},"NCT04409925","DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)",[86],"2021-04-01","2021-08-01","2020-12-25",15,[3497],"COVID-19 Infection",[3482],{"trials":3500,"activeCount":98},[],{"trials":3502,"activeCount":98},[],{"trials":3504,"activeCount":98},[],{"trials":3506,"activeCount":98},[],{"intervention":3508,"totalTrials":134,"cells":3509},"Sildenafil",{"EARLY_PHASE1":3510,"PHASE1":3512,"PHASE2":3524,"PHASE3":3526,"PHASE4":3528,"NA":3530},{"trials":3511,"activeCount":98},[],{"trials":3513,"activeCount":98},[3514],{"nctId":3515,"briefTitle":3516,"status":462,"phases":3517,"primaryCompletion":3518,"completion":2068,"start":3519,"enrollment":2639,"conditions":3520,"interventions":3522},"NCT02812433","Sildenafil Administration to Treat Neonatal Encephalopathy",[86],"2019-01","2016-07",[3521],"Neonatal Encephalopathy",[3508,3523],"Ora-Blend",{"trials":3525,"activeCount":98},[],{"trials":3527,"activeCount":98},[],{"trials":3529,"activeCount":98},[],{"trials":3531,"activeCount":98},[],{"intervention":3523,"totalTrials":134,"cells":3533},{"EARLY_PHASE1":3534,"PHASE1":3536,"PHASE2":3542,"PHASE3":3544,"PHASE4":3546,"NA":3548},{"trials":3535,"activeCount":98},[],{"trials":3537,"activeCount":98},[3538],{"nctId":3515,"briefTitle":3516,"status":462,"phases":3539,"primaryCompletion":3518,"completion":2068,"start":3519,"enrollment":2639,"conditions":3540,"interventions":3541},[86],[3521],[3508,3523],{"trials":3543,"activeCount":98},[],{"trials":3545,"activeCount":98},[],{"trials":3547,"activeCount":98},[],{"trials":3549,"activeCount":98},[],{"intervention":3551,"totalTrials":134,"cells":3552},"Temozolomide",{"EARLY_PHASE1":3553,"PHASE1":3555,"PHASE2":3567,"PHASE3":3569,"PHASE4":3571,"NA":3573},{"trials":3554,"activeCount":98},[],{"trials":3556,"activeCount":98},[3557],{"nctId":3558,"briefTitle":3559,"status":2019,"phases":3560,"primaryCompletion":3561,"completion":3562,"start":3563,"enrollment":98,"conditions":3564,"interventions":3566},"NCT03480867","Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)",[86],"2021-06","2023-11","2017-03",[3565],"Glioblastoma Multiforme, Adult",[3551],{"trials":3568,"activeCount":98},[],{"trials":3570,"activeCount":98},[],{"trials":3572,"activeCount":98},[],{"trials":3574,"activeCount":98},[],{"intervention":3576,"totalTrials":134,"cells":3577},"Camu Camu",{"EARLY_PHASE1":3578,"PHASE1":3580,"PHASE2":3590,"PHASE3":3592,"PHASE4":3594,"NA":3596},{"trials":3579,"activeCount":98},[],{"trials":3581,"activeCount":98},[3582],{"nctId":3583,"briefTitle":3584,"status":462,"phases":3585,"primaryCompletion":3586,"completion":3586,"start":3587,"enrollment":1049,"conditions":3588,"interventions":3589},"NCT04058392","Camu Camu in ART-treated People Living with HIV",[86],"2022-07-20","2020-11-09",[15],[3576],{"trials":3591,"activeCount":98},[],{"trials":3593,"activeCount":98},[],{"trials":3595,"activeCount":98},[],{"trials":3597,"activeCount":98},[],{"intervention":3599,"totalTrials":134,"cells":3600},"Doxepin and Zopiclone",{"EARLY_PHASE1":3601,"PHASE1":3611,"PHASE2":3613,"PHASE3":3615,"PHASE4":3617,"NA":3619},{"trials":3602,"activeCount":98},[3603],{"nctId":3604,"briefTitle":3605,"status":462,"phases":3606,"primaryCompletion":2379,"completion":2379,"start":3607,"enrollment":1208,"conditions":3608,"interventions":3610},"NCT01489982","Treatments for Insomnia in Patients With Parkinson's Disease",[85],"2011-01",[22,3609],"Insomnia",[3599],{"trials":3612,"activeCount":98},[],{"trials":3614,"activeCount":98},[],{"trials":3616,"activeCount":98},[],{"trials":3618,"activeCount":98},[],{"trials":3620,"activeCount":98},[],{"intervention":3622,"totalTrials":435,"cells":3623},"Lidocaine",{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3637,"PHASE4":3639,"NA":3641},{"trials":3625,"activeCount":98},[],{"trials":3627,"activeCount":98},[],{"trials":3629,"activeCount":98},[3630],{"nctId":3631,"briefTitle":3632,"status":462,"phases":3633,"primaryCompletion":1306,"completion":1306,"start":3634,"enrollment":1089,"conditions":3635,"interventions":3636},"NCT01155440","Bowel Function After Laparoscopic Colon Surgery: Effect of IV Lidocaine",[87],"2009-06",[3323,3324,3325],[3622],{"trials":3638,"activeCount":98},[],{"trials":3640,"activeCount":98},[],{"trials":3642,"activeCount":98},[3643,3652,3662],{"nctId":3644,"briefTitle":3645,"status":462,"phases":3646,"primaryCompletion":3647,"completion":3647,"start":3647,"enrollment":1856,"conditions":3648,"interventions":3650},"NCT01062906","Intravenous Lidocaine for Laparoscopic Cholecystectomy",[90],"2010-03",[32,3649],"Opioid Consumption",[3622,3651],"Fentanyl",{"nctId":3653,"briefTitle":3654,"status":462,"phases":3655,"primaryCompletion":3656,"completion":3657,"start":3658,"enrollment":1089,"conditions":3659,"interventions":3660},"NCT00982618","Functional Restoration After Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine",[90],"2010-06","2011-06","2009-07",[3323,3324,3325],[3622,3661],"PCA Morphine",{"nctId":3663,"briefTitle":3664,"status":108,"phases":3665,"primaryCompletion":3666,"completion":3666,"start":3667,"enrollment":2070,"conditions":3668,"interventions":3671},"NCT03862287","Incidence of TNS After Intrathecal Lidocaine v.s Bupivacaine",[90],"2019-12","2018-11-01",[3669,3670],"Orthopedic Disorder","Leg Injuries",[3622,3672],"Bupivacaine Hcl 0.5% Inj_#2",{"intervention":3674,"totalTrials":1036,"cells":3675},"Insulin",{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3682,"PHASE4":3684,"NA":3695},{"trials":3677,"activeCount":98},[],{"trials":3679,"activeCount":98},[],{"trials":3681,"activeCount":98},[],{"trials":3683,"activeCount":98},[],{"trials":3685,"activeCount":98},[3686],{"nctId":3687,"briefTitle":3688,"status":108,"phases":3689,"primaryCompletion":3690,"completion":3690,"start":2475,"enrollment":3691,"conditions":3692,"interventions":3694},"NCT02032953","Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia",[89],"2024-04",24,[3693],"Colorectal Cancer",[3674],{"trials":3696,"activeCount":98},[3697,3704],{"nctId":3698,"briefTitle":3699,"status":108,"phases":3700,"primaryCompletion":3518,"completion":3518,"start":3701,"enrollment":1208,"conditions":3702,"interventions":3703},"NCT03349489","Insulin-based Strategies to Prevent Hypoglycemia During Exercise",[90],"2018-05-18",[677],[3674],{"nctId":3705,"briefTitle":3706,"status":108,"phases":3707,"primaryCompletion":2475,"completion":3708,"start":3607,"enrollment":30,"conditions":3709,"interventions":3711},"NCT01271140","High Dose Insulin Therapy to Improve Liver Function",[90],"2014-06",[3710],"Hepatitis C Virus",[3674],{"intervention":2684,"totalTrials":94,"cells":3713},{"EARLY_PHASE1":3714,"PHASE1":3716,"PHASE2":3718,"PHASE3":3720,"PHASE4":3726,"NA":3728},{"trials":3715,"activeCount":98},[],{"trials":3717,"activeCount":98},[],{"trials":3719,"activeCount":98},[],{"trials":3721,"activeCount":98},[3722],{"nctId":2676,"briefTitle":2677,"status":108,"phases":3723,"primaryCompletion":746,"completion":2679,"start":2680,"enrollment":963,"conditions":3724,"interventions":3725},[87,88],[2682,27],[2684,2665],{"trials":3727,"activeCount":98},[],{"trials":3729,"activeCount":98},[3730],{"nctId":3731,"briefTitle":3732,"status":462,"phases":3733,"primaryCompletion":3734,"completion":3734,"start":3735,"enrollment":2728,"conditions":3736,"interventions":3737},"NCT05199714","A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes",[90],"2023-03-25","2022-02-21",[18],[3738,2684,3739],"Fiasp","Aspart",{"intervention":470,"totalTrials":94,"cells":3741},{"EARLY_PHASE1":3742,"PHASE1":3744,"PHASE2":3746,"PHASE3":3748,"PHASE4":3750,"NA":3756},{"trials":3743,"activeCount":98},[],{"trials":3745,"activeCount":98},[],{"trials":3747,"activeCount":98},[],{"trials":3749,"activeCount":98},[],{"trials":3751,"activeCount":98},[3752],{"nctId":460,"briefTitle":461,"status":462,"phases":3753,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":3754,"interventions":3755},[89],[468],[470,434],{"trials":3757,"activeCount":98},[3758],{"nctId":487,"briefTitle":488,"status":462,"phases":3759,"primaryCompletion":490,"completion":490,"start":491,"enrollment":492,"conditions":3760,"interventions":3761},[90],[494,495],[470,482,434],{"intervention":3763,"totalTrials":134,"cells":3764},"Temozolomide and Accelerated Hypofractionation RT",{"EARLY_PHASE1":3765,"PHASE1":3767,"PHASE2":3769,"PHASE3":3771,"PHASE4":3773,"NA":3775},{"trials":3766,"activeCount":98},[],{"trials":3768,"activeCount":98},[],{"trials":3770,"activeCount":98},[],{"trials":3772,"activeCount":98},[],{"trials":3774,"activeCount":98},[],{"trials":3776,"activeCount":98},[3777],{"nctId":3778,"briefTitle":3779,"status":462,"phases":3780,"primaryCompletion":3781,"completion":3781,"start":2835,"enrollment":336,"conditions":3782,"interventions":3784},"NCT01702610","Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme",[90],"2014-12",[3783],"Glioblastoma Mutliforme",[3763],{"intervention":3786,"totalTrials":134,"cells":3787},"Continuous Adductor Canal Block",{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3792,"PHASE3":3794,"PHASE4":3796,"NA":3798},{"trials":3789,"activeCount":98},[],{"trials":3791,"activeCount":98},[],{"trials":3793,"activeCount":98},[],{"trials":3795,"activeCount":98},[],{"trials":3797,"activeCount":98},[],{"trials":3799,"activeCount":98},[3800],{"nctId":3801,"briefTitle":3802,"status":462,"phases":3803,"primaryCompletion":3804,"completion":3805,"start":3806,"enrollment":1691,"conditions":3807,"interventions":3809},"NCT02680392","Functional Outcome and Analgesia in TKA: Radiofrequency vs Continuous Adductor Canal Block",[90],"2017-06-02","2017-07-07","2015-09-14",[3808],"Osteoarthritis, Knee",[3786],{"intervention":3811,"totalTrials":134,"cells":3812},"Sedatives",{"EARLY_PHASE1":3813,"PHASE1":3815,"PHASE2":3817,"PHASE3":3819,"PHASE4":3821,"NA":3823},{"trials":3814,"activeCount":98},[],{"trials":3816,"activeCount":98},[],{"trials":3818,"activeCount":98},[],{"trials":3820,"activeCount":98},[],{"trials":3822,"activeCount":98},[],{"trials":3824,"activeCount":98},[3825],{"nctId":3826,"briefTitle":3827,"status":108,"phases":3828,"primaryCompletion":3829,"completion":3829,"start":3830,"enrollment":1691,"conditions":3831,"interventions":3834},"NCT03345628","Feasibility Study for Neurodevelopment Follow-up Study in PICU",[],"2021-12-30","2018-02-01",[3832,3833],"Bronchiolitis Acute","Pneumonia",[3811],{"intervention":3836,"totalTrials":134,"cells":3837},"Skin biopsy",{"EARLY_PHASE1":3838,"PHASE1":3840,"PHASE2":3842,"PHASE3":3844,"PHASE4":3846,"NA":3848},{"trials":3839,"activeCount":98},[],{"trials":3841,"activeCount":98},[],{"trials":3843,"activeCount":98},[],{"trials":3845,"activeCount":98},[],{"trials":3847,"activeCount":98},[],{"trials":3849,"activeCount":98},[3850],{"nctId":3851,"briefTitle":3852,"status":462,"phases":3853,"primaryCompletion":3854,"completion":3855,"start":3856,"enrollment":1640,"conditions":3857,"interventions":3858},"NCT02767037","SudoScan as a Biomarker of Parkinson's Disease",[90],"2017-12","2018-06","2016-06",[22],[3836],{"intervention":3860,"totalTrials":134,"cells":3861},"Long-acting stimulant",{"EARLY_PHASE1":3862,"PHASE1":3864,"PHASE2":3866,"PHASE3":3868,"PHASE4":3870,"NA":3872},{"trials":3863,"activeCount":98},[],{"trials":3865,"activeCount":98},[],{"trials":3867,"activeCount":98},[],{"trials":3869,"activeCount":98},[],{"trials":3871,"activeCount":98},[],{"trials":3873,"activeCount":98},[3874],{"nctId":3875,"briefTitle":3876,"status":108,"phases":3877,"primaryCompletion":3878,"completion":3878,"start":2379,"enrollment":3879,"conditions":3880,"interventions":3882},"NCT02142140","Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)",[90],"2019-02",326,[3881],"Attention Deficit Hyperactivity Disorder (ADHD)",[3860,3860],{"intervention":3884,"totalTrials":134,"cells":3885},"Regular human insulin",{"EARLY_PHASE1":3886,"PHASE1":3888,"PHASE2":3890,"PHASE3":3892,"PHASE4":3894,"NA":3896},{"trials":3887,"activeCount":98},[],{"trials":3889,"activeCount":98},[],{"trials":3891,"activeCount":98},[],{"trials":3893,"activeCount":98},[],{"trials":3895,"activeCount":98},[],{"trials":3897,"activeCount":98},[3898],{"nctId":3899,"briefTitle":3900,"status":108,"phases":3901,"primaryCompletion":2379,"start":3656,"enrollment":963,"conditions":3902,"interventions":3904},"NCT01601561","The Effect of Insulin on Protein Metabolism After Cardiac Surgery",[90],[3903],"Cardiac Surgery",[3884],{"intervention":3906,"totalTrials":134,"cells":3907},"Inderal",{"EARLY_PHASE1":3908,"PHASE1":3910,"PHASE2":3912,"PHASE3":3914,"PHASE4":3916,"NA":3918},{"trials":3909,"activeCount":98},[],{"trials":3911,"activeCount":98},[],{"trials":3913,"activeCount":98},[],{"trials":3915,"activeCount":98},[],{"trials":3917,"activeCount":98},[],{"trials":3919,"activeCount":98},[3920],{"nctId":3921,"briefTitle":3922,"status":108,"phases":3923,"primaryCompletion":1058,"completion":1058,"start":1307,"enrollment":1089,"conditions":3924,"interventions":3926},"NCT01319214","Reducing Drug Craving Memories",[90],[3925],"Cocaine Addiction",[3906],{"intervention":3651,"totalTrials":134,"cells":3928},{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3939},{"trials":3930,"activeCount":98},[],{"trials":3932,"activeCount":98},[],{"trials":3934,"activeCount":98},[],{"trials":3936,"activeCount":98},[],{"trials":3938,"activeCount":98},[],{"trials":3940,"activeCount":98},[3941],{"nctId":3644,"briefTitle":3645,"status":462,"phases":3942,"primaryCompletion":3647,"completion":3647,"start":3647,"enrollment":1856,"conditions":3943,"interventions":3944},[90],[32,3649],[3622,3651],{"intervention":3738,"totalTrials":134,"cells":3946},{"EARLY_PHASE1":3947,"PHASE1":3949,"PHASE2":3951,"PHASE3":3953,"PHASE4":3955,"NA":3957},{"trials":3948,"activeCount":98},[],{"trials":3950,"activeCount":98},[],{"trials":3952,"activeCount":98},[],{"trials":3954,"activeCount":98},[],{"trials":3956,"activeCount":98},[],{"trials":3958,"activeCount":98},[3959],{"nctId":3731,"briefTitle":3732,"status":462,"phases":3960,"primaryCompletion":3734,"completion":3734,"start":3735,"enrollment":2728,"conditions":3961,"interventions":3962},[90],[18],[3738,2684,3739],{"intervention":3739,"totalTrials":134,"cells":3964},{"EARLY_PHASE1":3965,"PHASE1":3967,"PHASE2":3969,"PHASE3":3971,"PHASE4":3973,"NA":3975},{"trials":3966,"activeCount":98},[],{"trials":3968,"activeCount":98},[],{"trials":3970,"activeCount":98},[],{"trials":3972,"activeCount":98},[],{"trials":3974,"activeCount":98},[],{"trials":3976,"activeCount":98},[3977],{"nctId":3731,"briefTitle":3732,"status":462,"phases":3978,"primaryCompletion":3734,"completion":3734,"start":3735,"enrollment":2728,"conditions":3979,"interventions":3980},[90],[18],[3738,2684,3739],{"intervention":3982,"totalTrials":134,"cells":3983},"Meso-Jet, 2% lidocaine",{"EARLY_PHASE1":3984,"PHASE1":3986,"PHASE2":3988,"PHASE3":3990,"PHASE4":3992,"NA":3994},{"trials":3985,"activeCount":98},[],{"trials":3987,"activeCount":98},[],{"trials":3989,"activeCount":98},[],{"trials":3991,"activeCount":98},[],{"trials":3993,"activeCount":98},[],{"trials":3995,"activeCount":98},[3996],{"nctId":3997,"briefTitle":3998,"status":3999,"phases":4000,"primaryCompletion":4001,"completion":4002,"start":4003,"enrollment":963,"conditions":4004,"interventions":4007},"NCT04493528","Needle-free Dental Anesthesia","SUSPENDED",[90],"2023-12-15","2023-12-30","2019-07-18",[4005,4006],"Anesthesia, Local","Needle Phobia",[3982,4008],"Needle,2% lidocaine",{"intervention":4008,"totalTrials":134,"cells":4010},{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4017,"PHASE4":4019,"NA":4021},{"trials":4012,"activeCount":98},[],{"trials":4014,"activeCount":98},[],{"trials":4016,"activeCount":98},[],{"trials":4018,"activeCount":98},[],{"trials":4020,"activeCount":98},[],{"trials":4022,"activeCount":98},[4023],{"nctId":3997,"briefTitle":3998,"status":3999,"phases":4024,"primaryCompletion":4001,"completion":4002,"start":4003,"enrollment":963,"conditions":4025,"interventions":4026},[90],[4005,4006],[3982,4008],{"intervention":4028,"totalTrials":134,"cells":4029},"2% Lidocaine",{"EARLY_PHASE1":4030,"PHASE1":4032,"PHASE2":4034,"PHASE3":4036,"PHASE4":4038,"NA":4040},{"trials":4031,"activeCount":98},[],{"trials":4033,"activeCount":98},[],{"trials":4035,"activeCount":98},[],{"trials":4037,"activeCount":98},[],{"trials":4039,"activeCount":98},[],{"trials":4041,"activeCount":98},[4042],{"nctId":4043,"briefTitle":4044,"status":462,"phases":4045,"primaryCompletion":4046,"completion":1473,"start":4047,"enrollment":3691,"conditions":4048,"interventions":4050},"NCT01790464","Glossopharyngeal Nerve Block for Awake Intubation",[90],"2013-06","2012-04",[4049],"Morbid Obesity",[4028],{"intervention":4052,"totalTrials":134,"cells":4053},"dextrose 10% (D10W ®)",{"EARLY_PHASE1":4054,"PHASE1":4056,"PHASE2":4058,"PHASE3":4060,"PHASE4":4062,"NA":4064},{"trials":4055,"activeCount":98},[],{"trials":4057,"activeCount":98},[],{"trials":4059,"activeCount":98},[],{"trials":4061,"activeCount":98},[],{"trials":4063,"activeCount":98},[],{"trials":4065,"activeCount":98},[4066],{"nctId":4067,"briefTitle":4068,"status":462,"phases":4069,"primaryCompletion":4070,"completion":4070,"start":2333,"enrollment":1089,"conditions":4071,"interventions":4073},"NCT00774098","Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections",[90],"2009-09",[4072],"Liver Function",[4052,4074,4075],"hyperinsulinemic normoglycemic clamp","Intravenous normal saline",{"intervention":4074,"totalTrials":134,"cells":4077},{"EARLY_PHASE1":4078,"PHASE1":4080,"PHASE2":4082,"PHASE3":4084,"PHASE4":4086,"NA":4088},{"trials":4079,"activeCount":98},[],{"trials":4081,"activeCount":98},[],{"trials":4083,"activeCount":98},[],{"trials":4085,"activeCount":98},[],{"trials":4087,"activeCount":98},[],{"trials":4089,"activeCount":98},[4090],{"nctId":4067,"briefTitle":4068,"status":462,"phases":4091,"primaryCompletion":4070,"completion":4070,"start":2333,"enrollment":1089,"conditions":4092,"interventions":4093},[90],[4072],[4052,4074,4075],{"intervention":4075,"totalTrials":134,"cells":4095},{"EARLY_PHASE1":4096,"PHASE1":4098,"PHASE2":4100,"PHASE3":4102,"PHASE4":4104,"NA":4106},{"trials":4097,"activeCount":98},[],{"trials":4099,"activeCount":98},[],{"trials":4101,"activeCount":98},[],{"trials":4103,"activeCount":98},[],{"trials":4105,"activeCount":98},[],{"trials":4107,"activeCount":98},[4108],{"nctId":4067,"briefTitle":4068,"status":462,"phases":4109,"primaryCompletion":4070,"completion":4070,"start":2333,"enrollment":1089,"conditions":4110,"interventions":4111},[90],[4072],[4052,4074,4075],{"intervention":4113,"totalTrials":134,"cells":4114},"Radioactive Tracers",{"EARLY_PHASE1":4115,"PHASE1":4117,"PHASE2":4119,"PHASE3":4121,"PHASE4":4123,"NA":4125},{"trials":4116,"activeCount":98},[],{"trials":4118,"activeCount":98},[],{"trials":4120,"activeCount":98},[],{"trials":4122,"activeCount":98},[],{"trials":4124,"activeCount":98},[],{"trials":4126,"activeCount":98},[4127],{"nctId":4128,"briefTitle":4129,"status":108,"phases":4130,"primaryCompletion":4131,"completion":4132,"start":4133,"enrollment":1691,"conditions":4134,"interventions":4138},"NCT03049345","Gastric Cancer Sentinel Lymph Node Mapping",[90],"2022-06-30","2022-09-30","2016-07-01",[4135,4136,4137],"Gastric Cancer","Sentinel Lymph Node","Early Gastric Cancer",[4113,4139],"Methylene Blue 20 MG\u002FML",{"intervention":4139,"totalTrials":134,"cells":4141},{"EARLY_PHASE1":4142,"PHASE1":4144,"PHASE2":4146,"PHASE3":4148,"PHASE4":4150,"NA":4152},{"trials":4143,"activeCount":98},[],{"trials":4145,"activeCount":98},[],{"trials":4147,"activeCount":98},[],{"trials":4149,"activeCount":98},[],{"trials":4151,"activeCount":98},[],{"trials":4153,"activeCount":98},[4154],{"nctId":4128,"briefTitle":4129,"status":108,"phases":4155,"primaryCompletion":4131,"completion":4132,"start":4133,"enrollment":1691,"conditions":4156,"interventions":4157},[90],[4135,4136,4137],[4113,4139],{"intervention":4159,"totalTrials":134,"cells":4160},"Long-acting bronchodilator therapy",{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4165,"PHASE3":4167,"PHASE4":4169,"NA":4171},{"trials":4162,"activeCount":98},[],{"trials":4164,"activeCount":98},[],{"trials":4166,"activeCount":98},[],{"trials":4168,"activeCount":98},[],{"trials":4170,"activeCount":98},[],{"trials":4172,"activeCount":98},[4173],{"nctId":4174,"briefTitle":4175,"status":462,"phases":4176,"primaryCompletion":4177,"completion":4178,"start":4179,"enrollment":1785,"conditions":4180,"interventions":4182},"NCT06495047","Assessing Optimal Inhaler Strategies During Acute Exacerbations of COPD (AECOPDs) Using Oscillometry",[],"2025-06-30","2025-07-31","2025-06-01",[20,4181],"COPD Exacerbation Acute",[4159,4183],"Short-acting bronchodilator therapy",{"intervention":4183,"totalTrials":134,"cells":4185},{"EARLY_PHASE1":4186,"PHASE1":4188,"PHASE2":4190,"PHASE3":4192,"PHASE4":4194,"NA":4196},{"trials":4187,"activeCount":98},[],{"trials":4189,"activeCount":98},[],{"trials":4191,"activeCount":98},[],{"trials":4193,"activeCount":98},[],{"trials":4195,"activeCount":98},[],{"trials":4197,"activeCount":98},[4198],{"nctId":4174,"briefTitle":4175,"status":462,"phases":4199,"primaryCompletion":4177,"completion":4178,"start":4179,"enrollment":1785,"conditions":4200,"interventions":4201},[],[20,4181],[4159,4183],{"intervention":4203,"totalTrials":134,"cells":4204},"Tibolone 2.5 Mg Oral",{"EARLY_PHASE1":4205,"PHASE1":4207,"PHASE2":4209,"PHASE3":4211,"PHASE4":4213,"NA":4215},{"trials":4206,"activeCount":98},[],{"trials":4208,"activeCount":98},[],{"trials":4210,"activeCount":98},[],{"trials":4212,"activeCount":98},[],{"trials":4214,"activeCount":98},[],{"trials":4216,"activeCount":98},[4217],{"nctId":4218,"briefTitle":4219,"status":2019,"phases":4220,"primaryCompletion":4221,"completion":4221,"start":4222,"enrollment":98,"conditions":4223,"interventions":4226},"NCT05568940","Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids",[],"2026-04","2024-09",[4224,4225],"Endometriosis","Fibroids",[4203],{"intervention":4228,"totalTrials":134,"cells":4229},"Methylphenidate compounds and \u002For Amphetamine compounds and\u002For Strattera or Guanfacine",{"EARLY_PHASE1":4230,"PHASE1":4232,"PHASE2":4234,"PHASE3":4236,"PHASE4":4238,"NA":4240},{"trials":4231,"activeCount":98},[],{"trials":4233,"activeCount":98},[],{"trials":4235,"activeCount":98},[],{"trials":4237,"activeCount":98},[],{"trials":4239,"activeCount":98},[],{"trials":4241,"activeCount":98},[4242],{"nctId":4243,"briefTitle":4244,"status":108,"phases":4245,"primaryCompletion":1924,"completion":1924,"start":4246,"enrollment":1272,"conditions":4247,"interventions":4248},"NCT02788851","The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD)",[90],"2016-04",[3881],[4228],{"intervention":4250,"totalTrials":134,"cells":4251},"epidural fentanyl",{"EARLY_PHASE1":4252,"PHASE1":4254,"PHASE2":4256,"PHASE3":4258,"PHASE4":4260,"NA":4262},{"trials":4253,"activeCount":98},[],{"trials":4255,"activeCount":98},[],{"trials":4257,"activeCount":98},[],{"trials":4259,"activeCount":98},[],{"trials":4261,"activeCount":98},[],{"trials":4263,"activeCount":98},[4264],{"nctId":4265,"briefTitle":4266,"status":108,"phases":4267,"primaryCompletion":4268,"completion":3781,"start":4269,"enrollment":963,"conditions":4270,"interventions":4272},"NCT01646775","The Effect of Epidural Fentanyl on Immune Function",[90],"2014-10","2012-07",[4271],"Malignancy",[4250],{"intervention":3661,"totalTrials":134,"cells":4274},{"EARLY_PHASE1":4275,"PHASE1":4277,"PHASE2":4279,"PHASE3":4281,"PHASE4":4283,"NA":4285},{"trials":4276,"activeCount":98},[],{"trials":4278,"activeCount":98},[],{"trials":4280,"activeCount":98},[],{"trials":4282,"activeCount":98},[],{"trials":4284,"activeCount":98},[],{"trials":4286,"activeCount":98},[4287],{"nctId":3653,"briefTitle":3654,"status":462,"phases":4288,"primaryCompletion":3656,"completion":3657,"start":3658,"enrollment":1089,"conditions":4289,"interventions":4290},[90],[3323,3324,3325],[3622,3661],{"intervention":4292,"totalTrials":134,"cells":4293},"Atorvastatin; Fenofibrate; Niacin",{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4300,"PHASE4":4302,"NA":4304},{"trials":4295,"activeCount":98},[],{"trials":4297,"activeCount":98},[],{"trials":4299,"activeCount":98},[],{"trials":4301,"activeCount":98},[],{"trials":4303,"activeCount":98},[],{"trials":4305,"activeCount":98},[4306],{"nctId":4307,"briefTitle":4308,"status":462,"phases":4309,"primaryCompletion":2233,"completion":2233,"start":4310,"enrollment":2862,"conditions":4311,"interventions":4315},"NCT00458055","High-Density Lipoprotein (HDL) Treatment Study",[90],"2006-11",[4312,4313,4314],"Coronary Arteriosclerosis","Hypoalphalipoproteinemias","Genetic Diseases, Inborn",[4292],{"intervention":4317,"totalTrials":134,"cells":4318},"Amitriptyline Hydrochloride",{"EARLY_PHASE1":4319,"PHASE1":4321,"PHASE2":4323,"PHASE3":4325,"PHASE4":4327,"NA":4329},{"trials":4320,"activeCount":98},[],{"trials":4322,"activeCount":98},[],{"trials":4324,"activeCount":98},[],{"trials":4326,"activeCount":98},[],{"trials":4328,"activeCount":98},[],{"trials":4330,"activeCount":98},[4331],{"nctId":4332,"briefTitle":4333,"status":462,"phases":4334,"completion":4335,"start":4336,"enrollment":4337,"conditions":4338,"interventions":4341},"NCT00381199","Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia",[90],"2007-03","2006-04",32,[4339,4340],"Fibromyalgia","Sleep Initiation and Maintenance Disorders",[4317,4342],"Nabilone",{"intervention":4342,"totalTrials":134,"cells":4344},{"EARLY_PHASE1":4345,"PHASE1":4347,"PHASE2":4349,"PHASE3":4351,"PHASE4":4353,"NA":4355},{"trials":4346,"activeCount":98},[],{"trials":4348,"activeCount":98},[],{"trials":4350,"activeCount":98},[],{"trials":4352,"activeCount":98},[],{"trials":4354,"activeCount":98},[],{"trials":4356,"activeCount":98},[4357],{"nctId":4332,"briefTitle":4333,"status":462,"phases":4358,"completion":4335,"start":4336,"enrollment":4337,"conditions":4359,"interventions":4360},[90],[4339,4340],[4317,4342],{"intervention":4362,"totalTrials":134,"cells":4363},"Flumist®",{"EARLY_PHASE1":4364,"PHASE1":4366,"PHASE2":4368,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4365,"activeCount":98},[],{"trials":4367,"activeCount":98},[],{"trials":4369,"activeCount":98},[],{"trials":4371,"activeCount":98},[],{"trials":4373,"activeCount":98},[],{"trials":4375,"activeCount":98},[4376],{"nctId":4377,"briefTitle":4378,"status":108,"phases":4379,"primaryCompletion":1473,"completion":4380,"start":4381,"enrollment":478,"conditions":4382,"interventions":4384},"NCT01885169","LAIV (Flumist®) Administration in CF Patients",[],"2015-12","2013-08",[4383],"Cystic Fibrosis",[4362],{"intervention":4386,"totalTrials":134,"cells":4387},"Vitamin D",{"EARLY_PHASE1":4388,"PHASE1":4390,"PHASE2":4392,"PHASE3":4394,"PHASE4":4396,"NA":4398},{"trials":4389,"activeCount":98},[],{"trials":4391,"activeCount":98},[],{"trials":4393,"activeCount":98},[],{"trials":4395,"activeCount":98},[],{"trials":4397,"activeCount":98},[],{"trials":4399,"activeCount":98},[4400],{"nctId":4401,"briefTitle":4402,"status":2019,"phases":4403,"primaryCompletion":4269,"completion":4269,"start":1448,"enrollment":98,"conditions":4404,"interventions":4406},"NCT01400009","Vitamin D Replacement in Statin-Induced Myopathy",[90],[4405],"HMG COA Reductase Inhibitor Adverse Reaction",[4386],{"intervention":3672,"totalTrials":134,"cells":4408},{"EARLY_PHASE1":4409,"PHASE1":4411,"PHASE2":4413,"PHASE3":4415,"PHASE4":4417,"NA":4419},{"trials":4410,"activeCount":98},[],{"trials":4412,"activeCount":98},[],{"trials":4414,"activeCount":98},[],{"trials":4416,"activeCount":98},[],{"trials":4418,"activeCount":98},[],{"trials":4420,"activeCount":98},[4421],{"nctId":3663,"briefTitle":3664,"status":108,"phases":4422,"primaryCompletion":3666,"completion":3666,"start":3667,"enrollment":2070,"conditions":4423,"interventions":4424},[90],[3669,3670],[3622,3672],{"intervention":4426,"totalTrials":134,"cells":4427},"Regular insulin",{"EARLY_PHASE1":4428,"PHASE1":4430,"PHASE2":4432,"PHASE3":4434,"PHASE4":4436,"NA":4438},{"trials":4429,"activeCount":98},[],{"trials":4431,"activeCount":98},[],{"trials":4433,"activeCount":98},[],{"trials":4435,"activeCount":98},[],{"trials":4437,"activeCount":98},[],{"trials":4439,"activeCount":98},[4440],{"nctId":4441,"briefTitle":4442,"status":108,"phases":4443,"primaryCompletion":4444,"completion":4444,"start":4445,"enrollment":4446,"conditions":4447,"interventions":4450},"NCT03324867","The Effect of Intranasal Insulin Administration on Cognitive Function After Cardiac Surgery.",[90],"2023-04","2022-04",316,[4448,4449,115],"Cognitive Decline","Heart Diseases",[4426,4451],"Normal Saline Flush, 0.9% Injectable Solution",{"intervention":4451,"totalTrials":134,"cells":4453},{"EARLY_PHASE1":4454,"PHASE1":4456,"PHASE2":4458,"PHASE3":4460,"PHASE4":4462,"NA":4464},{"trials":4455,"activeCount":98},[],{"trials":4457,"activeCount":98},[],{"trials":4459,"activeCount":98},[],{"trials":4461,"activeCount":98},[],{"trials":4463,"activeCount":98},[],{"trials":4465,"activeCount":98},[4466],{"nctId":4441,"briefTitle":4442,"status":108,"phases":4467,"primaryCompletion":4444,"completion":4444,"start":4445,"enrollment":4446,"conditions":4468,"interventions":4469},[90],[4448,4449,115],[4426,4451],{"intervention":4471,"totalTrials":134,"cells":4472},"Vitamin D3",{"EARLY_PHASE1":4473,"PHASE1":4475,"PHASE2":4477,"PHASE3":4479,"PHASE4":4481,"NA":4483},{"trials":4474,"activeCount":98},[],{"trials":4476,"activeCount":98},[],{"trials":4478,"activeCount":98},[],{"trials":4480,"activeCount":98},[],{"trials":4482,"activeCount":98},[],{"trials":4484,"activeCount":98},[4485],{"nctId":4486,"briefTitle":4487,"status":1071,"phases":4488,"primaryCompletion":4489,"completion":4489,"start":3471,"enrollment":2045,"conditions":4490,"interventions":4492},"NCT01349764","Effect of Vitamin D Replacement in Patients With Urolithiasis",[],"2016-05",[4491],"Urolithiasis",[4471],{"intervention":4494,"totalTrials":134,"cells":4495},"lidocaine, bupivacaine, epinephrine, dexamethasone",{"EARLY_PHASE1":4496,"PHASE1":4498,"PHASE2":4500,"PHASE3":4502,"PHASE4":4504,"NA":4506},{"trials":4497,"activeCount":98},[],{"trials":4499,"activeCount":98},[],{"trials":4501,"activeCount":98},[],{"trials":4503,"activeCount":98},[],{"trials":4505,"activeCount":98},[],{"trials":4507,"activeCount":98},[4508],{"nctId":4509,"briefTitle":4510,"status":108,"phases":4511,"primaryCompletion":1924,"completion":1924,"start":4512,"enrollment":4513,"conditions":4514,"interventions":4516},"NCT03595514","Single Versus Double Injection Costoclavicular Block",[90],"2018-07-30",90,[4515],"Upper Extremity Injury",[4494],{"intervention":4518,"totalTrials":134,"cells":4519},"Esmolol",{"EARLY_PHASE1":4520,"PHASE1":4522,"PHASE2":4524,"PHASE3":4526,"PHASE4":4528,"NA":4530},{"trials":4521,"activeCount":98},[],{"trials":4523,"activeCount":98},[],{"trials":4525,"activeCount":98},[],{"trials":4527,"activeCount":98},[],{"trials":4529,"activeCount":98},[],{"trials":4531,"activeCount":98},[4532],{"nctId":4533,"briefTitle":4534,"status":462,"phases":4535,"primaryCompletion":2980,"completion":1783,"start":1715,"enrollment":1691,"conditions":4536,"interventions":4537},"NCT01275911","Non-opioid Analgesia for Fast-track Surgery",[90],[1338],[4518,4538],"Remifentanil",{"intervention":4538,"totalTrials":134,"cells":4540},{"EARLY_PHASE1":4541,"PHASE1":4543,"PHASE2":4545,"PHASE3":4547,"PHASE4":4549,"NA":4551},{"trials":4542,"activeCount":98},[],{"trials":4544,"activeCount":98},[],{"trials":4546,"activeCount":98},[],{"trials":4548,"activeCount":98},[],{"trials":4550,"activeCount":98},[],{"trials":4552,"activeCount":98},[4553],{"nctId":4533,"briefTitle":4534,"status":462,"phases":4554,"primaryCompletion":2980,"completion":1783,"start":1715,"enrollment":1691,"conditions":4555,"interventions":4556},[90],[1338],[4518,4538],{"intervention":4558,"totalTrials":134,"cells":4559},"TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and\u002For surgery.",{"EARLY_PHASE1":4560,"PHASE1":4562,"PHASE2":4564,"PHASE3":4566,"PHASE4":4568,"NA":4570},{"trials":4561,"activeCount":98},[],{"trials":4563,"activeCount":98},[],{"trials":4565,"activeCount":98},[],{"trials":4567,"activeCount":98},[],{"trials":4569,"activeCount":98},[],{"trials":4571,"activeCount":98},[4572],{"nctId":4573,"briefTitle":4574,"status":462,"phases":4575,"primaryCompletion":3519,"completion":3519,"start":1473,"enrollment":1208,"conditions":4576,"interventions":4578},"NCT02135627","TC-325 (HEMOSPRAY™) VS. CURRENT STANDARD OF CARE IN MANAGING MALIGNANT GASTROINTESTINAL BLEEDING: A PILOT STUDY TO INFORM A RANDOMIZED CONTROLLED TRIAL.",[90],[4577],"MALIGNANT GASTROINTESTINAL BLEEDING",[4558],{"intervention":4580,"totalTrials":134,"cells":4581},"Fluid challenge",{"EARLY_PHASE1":4582,"PHASE1":4584,"PHASE2":4586,"PHASE3":4588,"PHASE4":4590,"NA":4592},{"trials":4583,"activeCount":98},[],{"trials":4585,"activeCount":98},[],{"trials":4587,"activeCount":98},[],{"trials":4589,"activeCount":98},[],{"trials":4591,"activeCount":98},[],{"trials":4593,"activeCount":98},[4594],{"nctId":4595,"briefTitle":4596,"status":108,"phases":4597,"primaryCompletion":4598,"completion":447,"start":2727,"enrollment":4599,"conditions":4600,"interventions":4602},"NCT02418663","Fluid Responsiveness in the Postoperative Patient: a Prospective Study",[90],"2017-04",245,[4601],"Actual Impaired Fluid Volume",[4580],{"intervention":4604,"totalTrials":134,"cells":4605},"Albumin",{"EARLY_PHASE1":4606,"PHASE1":4608,"PHASE2":4610,"PHASE3":4612,"PHASE4":4614,"NA":4616},{"trials":4607,"activeCount":98},[],{"trials":4609,"activeCount":98},[],{"trials":4611,"activeCount":98},[],{"trials":4613,"activeCount":98},[],{"trials":4615,"activeCount":98},[],{"trials":4617,"activeCount":98},[4618],{"nctId":4619,"briefTitle":4620,"status":108,"phases":4621,"primaryCompletion":3051,"completion":3051,"start":1295,"enrollment":492,"conditions":4622,"interventions":4624},"NCT00842803","Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant",[90],[4623],"Liver Transplantation",[4604],{"intervention":4626,"totalTrials":134,"cells":4627},"Nintedanib 150 milligrams [Ofev]",{"EARLY_PHASE1":4628,"PHASE1":4630,"PHASE2":4632,"PHASE3":4634,"PHASE4":4636,"NA":4638},{"trials":4629,"activeCount":98},[],{"trials":4631,"activeCount":98},[],{"trials":4633,"activeCount":98},[],{"trials":4635,"activeCount":98},[],{"trials":4637,"activeCount":98},[],{"trials":4639,"activeCount":98},[4640],{"nctId":4641,"briefTitle":4642,"status":1071,"phases":4643,"primaryCompletion":533,"completion":4644,"start":4645,"enrollment":4646,"conditions":4647,"interventions":4650},"NCT05335278","Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease",[90],"2025-04-30","2021-06-01",11,[4648,4649],"Interstitial Lung Disease","Myopathy, Inflammatory",[4626],{"intervention":4652,"totalTrials":134,"cells":4653},"Biosimilar",{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4658,"PHASE3":4660,"PHASE4":4662,"NA":4664},{"trials":4655,"activeCount":98},[],{"trials":4657,"activeCount":98},[],{"trials":4659,"activeCount":98},[],{"trials":4661,"activeCount":98},[],{"trials":4663,"activeCount":98},[],{"trials":4665,"activeCount":98},[4666],{"nctId":4667,"briefTitle":4668,"status":108,"phases":4669,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4674,"interventions":4677},"NCT03729674","Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs",[],"2021-03-30","2022-12-31","2018-11-26",800,[1928,4675,4676,2238],"Ankylosing Spondylitis","Ulcerative Colitis",[4652,4678],"Originator (legacy) drug",{"intervention":4678,"totalTrials":134,"cells":4680},{"EARLY_PHASE1":4681,"PHASE1":4683,"PHASE2":4685,"PHASE3":4687,"PHASE4":4689,"NA":4691},{"trials":4682,"activeCount":98},[],{"trials":4684,"activeCount":98},[],{"trials":4686,"activeCount":98},[],{"trials":4688,"activeCount":98},[],{"trials":4690,"activeCount":98},[],{"trials":4692,"activeCount":98},[4693],{"nctId":4667,"briefTitle":4668,"status":108,"phases":4694,"primaryCompletion":4670,"completion":4671,"start":4672,"enrollment":4673,"conditions":4695,"interventions":4696},[],[1928,4675,4676,2238],[4652,4678],{"intervention":4698,"totalTrials":134,"cells":4699},"Besifloxacin",{"EARLY_PHASE1":4700,"PHASE1":4702,"PHASE2":4704,"PHASE3":4706,"PHASE4":4708,"NA":4710},{"trials":4701,"activeCount":98},[],{"trials":4703,"activeCount":98},[],{"trials":4705,"activeCount":98},[],{"trials":4707,"activeCount":98},[],{"trials":4709,"activeCount":98},[],{"trials":4711,"activeCount":98},[4712],{"nctId":4713,"briefTitle":4714,"status":462,"phases":4715,"primaryCompletion":4716,"completion":1524,"start":4717,"enrollment":4337,"conditions":4718,"interventions":4720},"NCT02497365","Besifloxacin in Bacterial Keratitis",[90],"2019-06","2015-09",[4719],"Bacterial Keratitis",[4698,4721],"Tobramycin and Cefazolin",{"intervention":4721,"totalTrials":134,"cells":4723},{"EARLY_PHASE1":4724,"PHASE1":4726,"PHASE2":4728,"PHASE3":4730,"PHASE4":4732,"NA":4734},{"trials":4725,"activeCount":98},[],{"trials":4727,"activeCount":98},[],{"trials":4729,"activeCount":98},[],{"trials":4731,"activeCount":98},[],{"trials":4733,"activeCount":98},[],{"trials":4735,"activeCount":98},[4736],{"nctId":4713,"briefTitle":4714,"status":462,"phases":4737,"primaryCompletion":4716,"completion":1524,"start":4717,"enrollment":4337,"conditions":4738,"interventions":4739},[90],[4719],[4698,4721],{"intervention":4741,"totalTrials":134,"cells":4742},"Sugammadex",{"EARLY_PHASE1":4743,"PHASE1":4745,"PHASE2":4747,"PHASE3":4749,"PHASE4":4751,"NA":4753},{"trials":4744,"activeCount":98},[],{"trials":4746,"activeCount":98},[],{"trials":4748,"activeCount":98},[],{"trials":4750,"activeCount":98},[],{"trials":4752,"activeCount":98},[],{"trials":4754,"activeCount":98},[4755],{"nctId":4756,"briefTitle":4757,"status":108,"phases":4758,"primaryCompletion":4759,"completion":4760,"start":4761,"enrollment":336,"conditions":4762,"interventions":4764},"NCT03791801","The Use of Sugammadex in the Critically Ill",[90],"2020-12-01","2021-07-01","2019-09-01",[4763],"Critical Illness",[4741,4765,4766,4767],"Neostigmine","Rocuronium","Glycopyrrolate",{"intervention":4765,"totalTrials":134,"cells":4769},{"EARLY_PHASE1":4770,"PHASE1":4772,"PHASE2":4774,"PHASE3":4776,"PHASE4":4778,"NA":4780},{"trials":4771,"activeCount":98},[],{"trials":4773,"activeCount":98},[],{"trials":4775,"activeCount":98},[],{"trials":4777,"activeCount":98},[],{"trials":4779,"activeCount":98},[],{"trials":4781,"activeCount":98},[4782],{"nctId":4756,"briefTitle":4757,"status":108,"phases":4783,"primaryCompletion":4759,"completion":4760,"start":4761,"enrollment":336,"conditions":4784,"interventions":4785},[90],[4763],[4741,4765,4766,4767],{"intervention":4766,"totalTrials":134,"cells":4787},{"EARLY_PHASE1":4788,"PHASE1":4790,"PHASE2":4792,"PHASE3":4794,"PHASE4":4796,"NA":4798},{"trials":4789,"activeCount":98},[],{"trials":4791,"activeCount":98},[],{"trials":4793,"activeCount":98},[],{"trials":4795,"activeCount":98},[],{"trials":4797,"activeCount":98},[],{"trials":4799,"activeCount":98},[4800],{"nctId":4756,"briefTitle":4757,"status":108,"phases":4801,"primaryCompletion":4759,"completion":4760,"start":4761,"enrollment":336,"conditions":4802,"interventions":4803},[90],[4763],[4741,4765,4766,4767],{"intervention":4767,"totalTrials":134,"cells":4805},{"EARLY_PHASE1":4806,"PHASE1":4808,"PHASE2":4810,"PHASE3":4812,"PHASE4":4814,"NA":4816},{"trials":4807,"activeCount":98},[],{"trials":4809,"activeCount":98},[],{"trials":4811,"activeCount":98},[],{"trials":4813,"activeCount":98},[],{"trials":4815,"activeCount":98},[],{"trials":4817,"activeCount":98},[4818],{"nctId":4756,"briefTitle":4757,"status":108,"phases":4819,"primaryCompletion":4759,"completion":4760,"start":4761,"enrollment":336,"conditions":4820,"interventions":4821},[90],[4763],[4741,4765,4766,4767]]